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ABSTRACT: A series of pleuromutilins modiﬁed by
introduction of a boron-containing heterocycle on C(14) of
the polycyclic core are described. These analogs were found to
be potent anti-Wolbachia antibiotics and, as such, may be
useful in the treatment of ﬁlarial infections caused by
Onchocerca volvulus, resulting in Onchocerciasis or river
blindness, or Wuchereria bancrofti and Brugia malayi and
related parasitic nematodes resulting in lymphatic ﬁlariasis. These two important neglected tropical diseases disproportionately
impact patients in the developing world. The lead preclinical candidate compound containing 7-ﬂuoro-6-oxybenzoxaborole (15,
AN11251) was shown to have good in vitro anti-Wolbachia activity and physicochemical and pharmacokinetic properties
providing high exposure in plasma. The lead was eﬀective in reducing the Wolbachia load in ﬁlarial worms following oral
administration to mice.
■ INTRODUCTION
Parasitic nematodes of the family Filarioidea including
Onchocerca volvulus, Wuchereria bancrofti, and Brugia malayi
are responsible for signiﬁcant disease burden in developing
countries around the world.1 Speciﬁcally, O. volvulus is the
parasite responsible for River Blindness, and W. bancrofti, B.
malayi, and Brugia timori cause lymphatic ﬁlariasis (elephan-
tiasis).2 Lymphatic ﬁlariasis is one of the leading causes of
global disability and accounts for at least 2.8 million disability-
adjusted life years. Treatment/control and elimination
programs for these infections have been in place for many
years, but fall short of full eﬀectiveness due to the demanding
treatment paradigm required to break disease transmission.3−5
More speciﬁcally, the long life span of adult worms (up to 15
years) requires annual to bi-annual mass drug administration of
therapeutics such as ivermectin which only kills the juvenile
microﬁlariae released by adult worms and sterilizes adult
worms but is not macroﬁlaricidal.5 Very recently, the results of
a triple-drug treatment (ivermectin, albendazole, and dieth-
ylcarbamazine) clinical trial demonstrated that this combina-
tion may require less frequent administration (perhaps once
every 3 years), but only a marginal improvement of
macroﬁlaricidal eﬀects over a dual-drug therapy was noted.6
Consequently, new approaches to kill the adult worms
(macroﬁlaricides) are required in order for elimination time-
frames of both diseases to be radically reduced. A short course
of treatment (7 days or fewer) would likely be required for ease
of implementation in the ﬁeld.
A unique feature of these parasitic worms is the presence of
obligate symbiotic bacteria of the Wolbachia genus.7 It has
been known for some time that classical antibacterial agents
such as doxycycline can kill the bacteria present in the worms,
which results in a reduced life span of the adult worm
itself.8−10 Unfortunately, doxycycline presents challenges as a
drug for mass administration, including the requirement for
long treatment periods (4−6 weeks) and contraindications in
pregnancy and in children.11 An anti-Wolbachia approach to
Received: November 27, 2018
Published: February 7, 2019
Article
pubs.acs.org/jmcCite This: J. Med. Chem. 2019, 62, 2521−2540
© 2019 American Chemical Society 2521 DOI: 10.1021/acs.jmedchem.8b01854
J. Med. Chem. 2019, 62, 2521−2540
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
D
ow
nl
oa
de
d 
vi
a 
LI
V
ER
PO
O
L 
SC
H
O
O
L 
TR
O
PI
CA
L 
M
ED
IC
IN
E 
on
 M
ar
ch
 1
5,
 2
01
9 
at
 0
9:
06
:1
2 
(U
TC
). 
Se
e 
ht
tp
s:/
/p
ub
s.a
cs
.o
rg
/sh
ar
in
gg
ui
de
lin
es
 fo
r o
pt
io
ns
 o
n 
ho
w
 to
 le
gi
tim
at
el
y 
sh
ar
e 
pu
bl
ish
ed
 a
rti
cl
es
. 
the treatment of ﬁlarial infections has a number of patient
beneﬁts especially as the co-endemic eyeworm Loa loa does
not harbor the endosymbiont and is therefore unaﬀected by
treatment. It has been observed that concurrent killing of L. loa
microﬁlariae by directly acting drugs in patients with >30 ;000
microﬁlariae per mL can have serious side eﬀects including
neurologic eﬀects, coma, and death.12 In addition, recent work
has suggested that depleting Wolbachia in worms can also
Figure 1. Pleuromutilin and clinically relevant derivatives.
Scheme 1. General Route to C(14)-Modiﬁed Boronpleuromutilins
Scheme 2. Route to C(12)-Modiﬁed Boronpleuromutilins
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diminish the number of microﬁlariae that are able to develop in
the insect vector, thus providing transmission blocking
activity.13 The underlying parasitology suggests that the
discovery and development of new anti-Wolbachia drugs
remains an attractive option for improving our ability to
reduce the global burden of river blindness and elephantiasis
and accelerate disease elimination goals.
As part of our ongoing eﬀort to capitalize on the unique
properties of benzoxaboroles in modifying pharmacologic,
physicochemical, and pharmacokinetic properties of existing
drug scaﬀolds, we prepared analogs of the antibiotic class
known as pleuromutilins.14,15 This class of ribosomal protein
synthesis inhibitors predominantly targets Gram-positive
bacteria and had been extensively explored since the 1950s,
but had not previously been shown to have activity against
Wolbachia. The pleuromutilins have been shown to inhibit
protein synthesis through binding to the peptidyl-transfer
center of the ribosome, with a crystal structure of tiamulin (4)
with the 50S subunit of Deinococcus radiodurans, providing the
most direct evidence of this mechanism of action.16 Recently,
Nabriva Therapeutics has been developing lefamulin (2),
which is currently in clinical trials for community-acquired
bacterial pneumonia, demonstrating the potential of this class
of antibiotic.17 Furthermore, the starting material for our
explorations, pleuromutilin (1), is readily available and
inexpensive with synthetic modiﬁcation, particularly of the
hydroxyacetate at C(14), being synthetically straightforward.
In addition to boronated analogs of the pleuromutilin core, we
also obtained or prepared several clinically relevant non-boron
analogs as summarized in Figure 1.18−21
■ RESULTS
The boronpleuromutilins modiﬁed at the C(14) position of
the pleuromutilin core were easily prepared via an SN2
displacement reaction of the pleuromutilin tosylate or iodide
(Scheme 1). These intermediates were synthesized from the
commercially available pleuromutilin. For compounds wherein
the vinyl group at C(12) was modiﬁed, ozonolysis of the
pleuromutilin tosylate with a reductive workup provided the
C(12) aldehyde (Scheme 2). Displacement of the C(14)
tosylate with 7-ﬂuoro-6-hydroxybenzoxaborole aﬀorded the
boronpleuromutilin, which in turn was condensed with
hydroxyl amines to provide the oximes, or with amines and
sodium cyanoborohydride to provide the amines. Hydro-
genation of the C(12) vinyl group of the boronpleuormutilin
aﬀorded the corresponding C(12) ethyl analog.
The boronpleuromutilins with a C(14)-carbamate linker
were prepared in two steps from 4-epi-pleuromutilin (72)22 in
a manner analogous to that described in the literature (Scheme
3).23 For example, following conversion of 72 to the carbamoyl
chloride 73, treatment with 6-aminobenzoxaborole 78
followed by a zinc chloride-mediated 1,5-hydride shift gave
the C(14)-carbamate 74. Compounds 75−77 were also
prepared in a similar manner.
The boron-containing heterocycles were prepared by a
variety of synthetic sequences that we have described in
previous publications.24 As an example, 7-ﬂuoro-6-hydrox-
ybenzoxaborole was prepared by the route shown in Scheme 4.
Protection of 3,4-diﬂuorophenol (79) as the methoxymethyl
ether was followed by ortho-metallation and trapping of the
intermediate aryllithium with ethyl formate to provide the
benzaldehyde derivative 81. Nucleophilic displacement of the
para ﬂuorine with benzyl alcohol under basic conditions
provided 82. Deprotection of the methoxymethyl ether
followed by conversion to triﬂate 84 permitted introduction
of the boron via palladium-mediated borylation. Reduction of
the aldehyde 85 with sodium borohydride followed by
treatment with aqueous hydrochloric acid resulted in
formation of the benzoxaborole 86. Finally, hydrogenolysis
Scheme 3. Route to C(14) Boronpleuromutilin Carbamates
Scheme 4. Synthesis of 7-Fluoro-6-hydroxybenzoxaborole
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of the benzyl ether gave the desired 7-ﬂuoro-6-hydroxybenzox-
aborole intermediate 87.
We screened the pleuromutilin drug candidates in two
primary in vitro assays that diﬀered in the strain of Wolbachia
used, the insect cell line used to host the bacteria, and in the
method of detection.25,26 We used data from both assays to
help ensure robust selection of compounds for progression to
subsequent in vitro ADME and in vivo pharmacokinetics (PK)
experiments. While the absolute potency of individual
compounds varied between the two assays in some cases, the
structure−-activity relationship (SAR) trends observed in these
assays were generally similar. Initial screening revealed that
several of the clinically relevant pleuromutilins, for example,
retapamulin (3) and valnemulin (5), showed good activity in
in vitro assays; signiﬁcantly less activity was observed for
lefamulin (2), tiamulin (4), or for the unadorned pleuromutilin
core (1, Table 1). More interestingly, attachment of a
benzoxaborole ring with either an oxygen (8), nitrogen (25),
or sulfur (33) linker at the 6-position to the C(14) sidechain
provided compounds (hereafter referred to as boronpleur-
omutilins) of similar in vitro potency to valnemulin and
retapamulin. Introduction of a methylene spacer between the
pleuromutilin core and the benzoxaborole ring as in 35
signiﬁcantly reduced potency. Attachment of the benzoxabor-
ole ring via the 5- position also provided compounds (37−39)
with signiﬁcantly reduced in vitro activity.
We next turned our attention to substitution of the
benzoxaborole core, where we found that introduction of a
Table 1. Pleuromutilin Derivatives with Benzoxaboroles Linked via C(14)
ID
link
atom X R
Wolbachia infected C6/36 cells (wAlb) EC50
(nM)
Wolbachia infected LDW1 cells (wMel) EC50
(nM)
1 (pleuromutilin) NAa OH NA >1000 6868
2 (lefamulin) NA NA NA 205 220
3 (retapamulin) NA NA NA NTb 91
4 (tiamulin) NA NA NA 317 606
5 (valnemulin) NA NA NA NT 6.1
8 6 O H 6.3 1.3
9 6 O 3-Me (R,S) 215 24
10 6 O 4-Me 100 28
11 6 O 5-Me 11 2.8
12 6 O 7-Me 52 2.9
13 6 O 4-F 158 19
14 6 O 5-F 8.4 NT
15 6 O 7-F 15 1.5
16 6 O 7-Cl 32 14
17 6 O 7-OMe NT 3.7
18 6 O 5,7-F2 NT 1.2
19 6 O 3-CH2NH2 104 19
20 6 O 4-CH2NH2 64 18
21 6 O 7-Cl, 3-CH2NH2 197 49
22 6 O 7-F, 3-CH2NH2 >1000 317
23 6 O 7-Cl, 4-CH2NH2 50 9
24 6 O 3,3-Me2 >10 000 148
25 6 NH H 5.0 4.1
26 6 NH 3-CH2NH2 229 17
27 6 NH 4-CH2NH2 409 44
28 6 NH 5-CH2NH2 302 1182
29 6 NH 7-CH2NH2 257 173
30 6 NH 3,3-Me2 >1000 198
31 6 NH 5-F 23 NT
32 6 NH 7-F 106 13
33 6 S H 123 17
34 6 S 7-F NT 15
35 6 −CH2NH− H >1000 243
36 6 −CH2NH− 3,3-Me2 >10 000 1418
37 5 O H >10 000 NT
38 5 O 5-F 298 39
39 5 O 7-F 149 NT
aNA = not applicable. bNT = not tested.
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ﬂuoro substituent at the 4- (13), 5- (14) or 7- (15) positions
was generally tolerated with the C(7) analog 15 exhibiting very
potent activity. Other small substituents at C(7) such as
methyl (12), chloro (16), or methoxy (17) were also tolerated,
but did not improve activity beyond the ﬂuoro analog. As the
pleuromutilins are intrinsically very lipophilic, we also
examined introduction of an aminomethyl substituent onto
the benzoxaborole core (19−23, 26−29), but these analogs
were generally less active than the corresponding neutral
compounds. Finally, we found that addition of two methyl
groups at C(3) of the benzoxaborole (24, 30), a strategy that
had improved pharmacokinetic properties in other series,27
signiﬁcantly reduced potency.
Initial results with other boron-containing heterocycles
linked via C(14) of the pleuromutilin core were encouraging,
as a number of these analogs were very potent in the in vitro
Wolbachia assay (Table 2). In particular, the N-methanesul-
fonyl (40), N-acetyl (42), and N-methylcarbamoyl (45)
derivatives of the diazaborine scaﬀold exhibited low nanomolar
to picomolar potency. Unlike the benzoxaboroles, however,
inclusion of a ﬂuorine atom adjacent to the B−OH did not
improve potency; in fact, these derivatives (47−51) were
signiﬁcantly less potent. The benzoxaborine 53, wherein the
ﬁve-membered ring was expanded by one carbon to a six
membered ring, was completely inactive.
We also explored modiﬁcation of the C(12) vinyl
substituent (Table 3). Work in the classical pleuromutilin
literature had shown that this double bond could be reduced to
provide an ethyl group (54), converted to the epoxide (55) or
oxidized to an aldehyde (58) that could be functionalized in a
variety of ways.28 In particular, we sought to introduce small
amines at C(12) to modify physicochemical and pharmacoki-
netic properties. Given the interesting properties of 15 (vide
supra), this work was performed with the 7-ﬂuoro-6-
oxobenzoxaborole linked via to C(14) of the pleuromutilin
core.
Disappointingly, only the ethyl (54) derivative exhibited
potency close to the C(12) vinyl analog 15; oximes (60−62)
and amines (63−70) were signiﬁcantly less potent. Some
potency was regained by acylation of the amine (71), but this
was not perceived as being of suﬃcient advantage to pursue
further.
As a ﬁnal area of exploration, we prepared several
boronpleuromutilins where the C(14)-hydroxyacetate linker
was replaced by a shorter carbamate (Table 4). This strategy
had previously been explored in the pleuromutilins as a means
to improve oral bioavailability.23 The carbamates prepared
(74−77) exhibited moderate-to-good in vitro potency.
Concurrent with our evaluation of the in vitro potency of the
boronpleuromutilins, we also selected a number of active
analogs for characterization in both in vitro absorption,
Table 2. Pleuromutilins with Other Boron Heterocycles
Linked via C(14)
ID P Q−R R8
Wolbachia
infected
C6/36 cells
(wAlb) EC50
(nM)
Wolbachia
infected
LDW1 cells
(wMel)
EC50 (nM)
40 CH3SO2N NCH H 9 0.8
41 CH3N NCH H 14.8 1.5
42 CH3C(O)N NCH H 4 0.2
43 Boc-N NCH H 0.7 0.2
44 HN NCH H 3.5 2.7
45 CH3OC(O)N NCH H 1.5 0.3
46 O NCH H 14.2 5.1
47 CH3SO2N NCH 8-F 240 6.3
48 CH3N NCH 8-F 172 11
49 CH3C(O)N NCH 8-F 107 NTa
50 CH3OC(O)N NCH 8-F 164 1.3
51 O NCH 8-F 329 27
52 CH3C(O)N NCH 8-CH3 26.1 NT
53 O CH2CH2 H >1000 NT
aNT = not tested.
Table 3. Boronpleuromutilins Modiﬁed at C(12)
ID Rb
Wolbachia infected
C6/36 cells (wAlb)
EC50 (nM)
Wolbachia infected
LDW1 cells (wMel)
EC50 (nM)
54 CH3CH2− 38 2.7
55 epoxide 148 13
58 OHC− 278 33
59 HOCH2− >1000 242
60 HONCH− >1000 71
61 CH3ONCH− 197 39
62 iso-C3H7ONCH− NTa 101
63 H2NCH2− >1000 6892
64 CH3NHCH2− >1000 1718
65 C2H5NHCH2− 474 1399
66 n-C3H7NHCH2− 357 478
67 n-C4H9NHCH2 372 243
68 cyclo-C3H5NHCH2 115 44
69 (CH3)2NCH2− 328 439
70 CH3ONHCH2− NT 133
71 CH3C(O)NHCH2− >1000 29
aNT = not tested.
Table 4. Boronpleuromutilin Carbamates
ID X Ra
Wolbachia infected
C6/36 cells (wAlb) EC50
(nM)
Wolbachia infected
LDW1 cells
(wMel) EC50 (nM)
74 bond H 101 7.5
75 bond 5-F >1000 14
76 CH2 H 12 3.5
77 CH2 7-F 113 4.9
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distribution, metabolism, excretion (ADME) and in vivo PK
experiments. It has been suggested that one of the main
limitations of the pleuromutilins is high metabolic instability
leading to poor PK.29,30 In fact, the majority of the clinically
relevant pleuromutilins are of limited oral bioavailability, which
has hampered their utility for human applications. A notable
exception is the recently described lefamulin (2), which is
currently in phase 3 clinical trials as an oral treatment for a
variety of bacterial infections.31,32 In order to calibrate our
expectations for the boronpleuromutilins, we screened several
of the clinically relevant analogs in our in vitro ADME assays as
well (Table 5). As anticipated, tiamulin and retapamulin were
found to be rapidly metabolized by mouse liver S9 fraction,
whereas lefamulin was slowly metabolized. These classical
pleuromutilins exhibited a range of binding to mouse plasma
proteins, with free fraction ( f unbound) from 0.05−0.26. Slightly
surprisingly, we found that lefamulin was not particularly
permeable in our MDR1-MDCK assay, though the high
stringency of this assay may underestimate the permeability of
this compound through the gut. We had chosen the MDR1-
MDCK assay to assess permeability over the related Caco2
assay due to throughput and the opportunity to more directly
assess the impact of P-glycoprotein-mediated eﬄux in this cell
line. In addition, it has also been reported that the MDR1-
MDCK is an acceptable assay for evaluation of the
permeability of compounds through the intestinal mucosa of
humans.33
The neutral boronpleuromutilins evaluated (8−12, 14, 25,
33) were generally metabolized quickly by mouse S9 (Clint >
50 μL/min/mg), were highly protein bound ( f unbound < 0.03),
and were predicted to have good permeability based on the
MDR1-MDCK assay (Papp > 5 × 10
−6 cm/s). In contrast,
boronpleuromutilins bearing an aminomethyl substituent
(19−21, 23, 26) were less rapidly metabolized (Clint < 10
μL/min/mg), much less protein bound ( f unbound > 0.1), but
were predicted to be of low permeability (Papp < 1 × 10
−6 cm/
s). Later compounds incorporating boron-containing hetero-
cycles other than the benzoxaborole (40−42, 44−46, 52, 53)
or modiﬁcation of C(12) (55, 59) did not signiﬁcantly change
the overall in vitro ADME proﬁle. One compound that stood
out as having an attractive balance of properties was the 7-
ﬂuorobenzoxaborole derivative 15, which exhibited modest
clearance (Clint = 33 μL/min/mg) and protein binding
( f unbound = 0.03), and good permeability (Papp = 14.1 × 10
−6
cm/s).
Based on these in vitro proﬁles and due to resource
constraints, we selected representative compounds from the
various classes (e.g., neutral, aminomethyl), diﬀerent linkers
(e.g., O, N) and boron heterocycles (e.g., benzoxaboroles,
diazaborines) for progression to in vivo PK experiments as
summarized in Table 6. When the in vivo PK in mice of these
representative compounds were measured, we observed that
the PK parameters between them were variable following both
IV and oral administration, consistent with the in vitro
properties described above. Several observations were made
from these studies. First, and as expected, clearance following
intravenous dosing was generally quite high, with only
compound 15 exhibiting low-to-modest clearance. Second,
incorporation of an aminomethyl group on the benzoxaborole
core (19) signiﬁcantly reduced oral bioavailability, as did
replacement of the benzoxaborole with a diazaborine (45, 52).
Table 5. In Vitro ADME Properties of Boronpleuromutilins
ID
mouse S9 Clint
(μL/min/mg)
mouse protein binding
( f unbound @ 2 μM)
MDR1-MDCK
Papp
a
2 4 0.218 0.2
3 41 0.154 6.7
4 131 0.26b 22.1
5 NT 0.05b 1.4
8 145 0.003 15.1
9 168 0.002 NTc
10 139 0.005 NT
11 77 <0.001 NT
12 136 0.012 NT
14 117 0.003 NT
15 33 0.034 14.1
16 44 0.008 NT
19 NT 0.116 0.3
20 7 0.110 0.1
21 NT 0.119 0.5
23 NT 0.048 0.1
25 102 0.008 36.5
26 2 0.306 0.1
32 NT 0.005 22.6
33 142 0.008 9.0
40 226 0.058 6.6
41 NT 0.007 NT
42 NT 0.005 NT
44 80 0.008 2.3
45 NT 0.037 NT
46 NT <0.001 8.8
52 217 0.006 NT
53 NT <0.001 NT
55 NT NT 8.7
59 53 0.033 3.7
aPermeability measured in a Madin Darby canine kidney cell
monolayer transfected with the multidrug resistance 1 (mdr1) gene
encoding P-glycoprotein MDR1. bProtein binding measured at 1 μM.
cNT = not tested.
Table 6. In Vivo Pharmacokinetic Properties of Lead Boronpleuromutilins in BALB/c Mice
IV at 5 mg/kg, vehicle 55/25/20 PEG/PG/H2O PO at 10 mg/kg, vehicle 55/25/20 PEG/PG/H2O
Cmpd Cmax (μg/mL) CL (mL/hr/kg) Vss (mL/kg) AUC0−last (h μg/mL) Cmax (μg/mL) AUC0−last (h μg/mL) % F
8 4.13 2296 2716 2.18 0.673 1.54 35
15 3.21 505 4186 8.85 1.60 12.1 61
19 2.48 2120 10 435 2.26 0.003 0.02 <1
32 5.91 1080 2231 4.60 1.66 11.0 ∼100
45 7.40 1642 854 3.03 0.262 0.425 7
52 3.22 3273 4658 1.52 0.227 0.166 6
77 3.91 1338 2561 3.71 1.09 8.51 ∼100
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Finally, oral exposure and bioavailability was generally good for
the 7-ﬂuorobenzoxaborole derivatives tested (15, 32, and 77).
Given the relatively low clearance and high exposure
exhibited by 15, coupled with its good biological potency,
additional PK experiments were performed with this
compound. These conﬁrmed the attractive PK proﬁle
following oral administration to mice of 15, as systemic
exposures at doses from 10 to 50 mg/kg were good, with Cmax
values increasing dose-dependently, while AUC values
remained relatively constant, suggesting dissolution-limited
absorption of the compound from the gut (Table 7).
Based on this combination of in vitro potency and in vivo
PK data, we next examined the ability of 15 to deplete the
Wolbachia symbiont from ﬁlarial worms in vivo. In all in vivo
eﬃcacy assays, depletion ofWolbachia was determined through
comparison to the Wolbachia load found in worms present in
animals that were treated with only the dosing vehicle as
described in the Experimental Section. For our initial in vivo
screen, groups of three CB.17 SCID mice were inoculated with
50 L3-stage B. malayi larvae via the peritoneal cavity and
treated from point of infection with 15 for 7 or 14 days with
oral doses of 25 mg/kg, BID. At point of necropsy, on day 14,
fourth stage (L4) B. malayi larvae were isolated from the
peritoneal cavity. Larvae were pooled per group and intraworm
Wolbachia titers were quantiﬁed from groups of 10 larvae using
qPCR. Included in the same experiment were a vehicle control
group and two groups of doxycycline-treated animals as
positive controls. We were encouraged to ﬁnd that 15 reduced
theWolbachia load in the B. malayi larvae by 75.4 and 98.8% in
the 7- and 14-day treatment groups, respectively. In this
experiment, doxycycline reduced Wolbachia load by 76.3 and
96.7% following 7- and 14-day treatment at 50 mg/kg, QD,
respectively (Table 8).
Values represent percent (%) median reduction of
Wolbachia versus the vehicle control, as measured by qPCR
of Wolbachia surface protein single copy gene (wsp) per B.
malayi L4 larva (n = 10 per group) obtained from necropsies
undertaken 2 weeks after ﬁrst dose.
Encouraged by the proﬁle of 15, and in preparation for more
extensive in vivo characterization of this molecule, we
conducted a number of preliminary in vitro and in vivo
studies to assess the safety of this molecule. In a non-GLP
Ames assay (Bioreliance, Rockville, MD), 15 was determined
to be nonmutagenic. Furthermore, 15 was found to be negative
in its potential to induce micronuclei in human peripheral
blood lymphocytes (Bioreliance, Rockville, MD). In a panel of
over 50 mammalian receptors, enzymes and ion channels
(Euroﬁns Cerep, France), 15 was found to be without any
signiﬁcant eﬀect at 10 μM, and it was also shown to have no
signiﬁcant (<10%) eﬀect on the hERG potassium channel
expressed in HEK cells at a concentration of 30 μM
(ChanTest, Cleveland, OH). Finally in a preliminary safety
study (Anacor, Palo Alto, CA), no adverse eﬀects were
observed in BALB/c mice treated with 15 at doses up to 200
mg/kg/day for 7 days.
We next progressed 15 to chronic in vivo infection models
of adult ﬁlarial parasitism (the target life cycle stage for an anti-
Wolbachia indication); one using B. malayi and one using
Litomosoides sigmodontis. We initially chose to use the B. malayi
SCID mouse model34 as this worm species is a causative agent
of LF in humans.2 In this B. malayi assay, 100 L3-stage larvae
were inoculated via the peritoneal route and adult infections
were allowed to develop. At 6-weeks post-infection, the mice
were treated with 15 (25 mg/kg, BID) for 7, 14, or 28 days. At
the end of the experiment (12-week post-infection), worms
were recovered from the mice and Wolbachia load was
determined by qPCR. In this experiment, vehicle and
minocycline (25 mg/kg, BID × 28 days) groups were included
as negative and positive controls, respectively. Minocycline was
Table 7. In Vivo Pharmacokinetic Properties of 7-Fluorobenzoxaborole Analog 15 in BALB/c Mice
15 IV
5 mg/kg (mean, n = 3)
vehicle 55/25/20 PEG/PG/H2O
Cmax (μg/mL) @ 5 min 3.21 ± 1.3
CL (mL/h/kg) 505
Vss (mL/kg) 4186
AUClast (h μg/mL) 8.85
AUC0−inf (h μg/mL) 9.91
terminal t1/2 (h) 9.10
15 PO
10 mg/kg solution
(mean, n = 3)
10 mg/kg suspension
(mean, n = 3)
25 mg/kg suspension
(mean, n = 3)
50 mg/kg suspension
(mean, n = 3)
vehicle 55/25/20 PEG/PG/H2O 1% CMC, 0.1% Tween 80 in H2O 1% CMC, 0.1% Tween 80 in H2O 1% CMC, 0.1% Tween 80 in
H2O
Cmax (μg/mL) 1.60 2.81 4.25 6.38
Tmax (h) 0.083 0.50 0.25 0.50
AUClast (h μg/mL) 12.1 20.7 23.7 23.0
AUC0−inf(h μg/mL) 14.0 22.8 24.2 NC
a
terminal t1/2 (h) 8.41 7.51 4.60 NC
bioavailability (%) 61.1 NC NC NC
aNC = not calculated.
Table 8. Summary of Eﬃcacy of 15 and Doxycycline in
Reduction of Wolbachia in a Larval B. malayi SCID Mouse
Model
dosing duration 7 days 14 days
doxycycline, 50 mg/kg QD 76.3% 96.7%
15, 25 mg/kg, BID 75.4% 98.8%
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chosen as the positive control for this study based on
concurrent results in an L. sigmondontis model (vide infra),
which suggested that this tetracycline antibiotic exhibited
superior eﬃcacy to doxycycline.35 Slightly disappointingly,
eﬃcacy of 15 was not nearly as good in the adult model, with a
45.5% reduction of Wolbachia load observed for the 28 day
treatment group. By comparison, minocycline provided 98.2%
reduction in this experiment (Table 9). We hypothesize that
the failure of 15 to show eﬃcacy at the dose chosen in the B.
malayi adult worm model is likely due to the increased
washout period between treatment start and necropsy in
comparison to the B. malayi L3 larval model, leading to a
rebound of the Wolbachia with a suboptimal treatment
regimen of 15.
Values represent percent (%) median reduction of
Wolbachia versus the vehicle control, as measured by qPCR
of Wolbachia surface protein single copy gene (wsp) per adult
female B. malayi (n = 10 per group) obtained from necropsies
undertaken 6 weeks after ﬁrst dose.
In a second eﬃcacy model,35,36 we used mice infected with
the rodent ﬁlarial nematode L. sigmodontis, another helminth
species known to host Wolbachia, and treated these animals
with 15 at a dose of 50 mg/kg, BID for 14 or 28 days. The L.
sigmodontis model was chosen as an additional, conﬁrmatory
ﬁlarial model as it uses immunocompetent wild-type mice as
host and initial studies demonstrated the eﬃcacy of
tetracycline against Wolbachia-containing ﬁlariae ﬁrst in this
model.37 In addition, the infection could be maintained in mice
using a natural infection protocol.35,38−40 Upon completion of
dosing, animals were maintained for a total of 64−77 days (to
maintain a consistent total time following the ﬁnal dose), at
which time worms were recovered from the peritoneum and
the thoracic cavity. Wolbachia load was determined by qPCR.
Doxycycline was included as a positive control in this
experiment. We were encouraged to ﬁnd that 15 was able to
reduce Wolbachia burden in L. sigmodontis by >99% at this
dose and duration (Table 10). The stronger reduction of the
Wolbachia load in the L. sigmodontis mouse model in
comparison to the adult B. malayi mouse model is probably
mostly due to the increased dose used for treatment with 15,
although L. sigmodontis were previously reported to have an
increased susceptibility for anti-Wolbachia drugs compared to
B. malayi ﬁlariae.41
Values represent percent (%) reduction of Wolbachia versus
the untreated control, as measured by qPCR FtsZ/actin per
mouse, and were obtained from necropsies performed 1 month
after ﬁrst dose.
■ DISCUSSION AND CONCLUSIONS
Previous work from our laboratories has demonstrated that
boron-containing heterocycles can be useful in the treatment
of various diseases, including infectious diseases of the
developing world such as malaria,42,43 human African
trypanosomiasis,27,44 and tuberculosis.45,46 We have extended
our work to look at modiﬁcation of known classes of
antibacterial agents as an approach to treat river blindness
via the bacterial symbiont (Wolbachia) present in the worms
that cause this disease. Clear clinical “proof of concept” for an
anti-Wolbachia approach has been demonstrated with the
tetracycline antibiotic doxycycline.9 The utility of doxycycline
is limited, however, by the requirement that patients must be
treated for 4−6 weeks in order to achieve signiﬁcant reduction
of Wolbachia in the O. volvulus parasite.8−10 More recently, it
has been demonstrated that combination of doxycycline (200
mg/day for 3 weeks) with albendazole (800 mg/day for 3
days) may provide a shorter treatment course.47 While moving
closer to the desired short course (7 day or fewer) treatment
paradigm, this combination therapy is still not ideal and does
not address tetracycline contraindicated groups (children of
age ≤8 and pregnant women).
Our work started by evaluating representatives of various
classes of antibiotics including several clinically relevant
pleuromutilins. This initial screening revealed that some
activity was present in this class of compounds, and we
prepared several analogs containing our benzoxaborole core.
The synthesis of these boronpleuromutilins was facilitated by
the ready availability of the tosylate derivative of the
hydroxyacetate ester at C(14) of the pleuromutilin core.
Simple nucleophilic displacement reactions of this to aﬀord
C(14)-functionalized boronpleuromutilins with nitrogen, oxy-
gen, or sulfur linker atoms proceeded in good yield. Early SARs
revealed that direct attachment of the benzoxaborole ring to
the pleuromutilin core provided compounds with good in vitro
potency. In contrast, inclusion of a linker group such as present
in the clinically relevant pleuromutilins between the core and
benzoxaborole ring were of poor activity. Based on our
previous work in the benzoxaboroles, we focused our attention
on compounds linked through the 6-position, as these were
both synthetically accessible and generally had been observed
to have good ADME properties. Inclusion of a variety of
substituents such as halogen, small alkyl, or aminoalkyl at
positions 3, 4, 5, and 7 of the 6-O linked benzoxaboroles gave
compounds of similar in vitro activity and allowed us to
explore the eﬀect of these substituents on ADME and PK. We
were particularly pleased to ﬁnd that the 7-ﬂuoro analog (15)
exhibited a good balance of potency and physicochemical and
ADME properties. In particular, we were encouraged by the
modest metabolic stability in mouse microsomes (Clint = 33
μL/min/mg) and good permeability through an MDR1-
MDCK monolayer (Papp = 14.1 × 10
−6 cm/s). We were
slightly concerned about the high protein binding of 15
( f unbound = 0.03), though this was predicted based on the
calculated high lipophilicity (log D 4.23) of this compound.
While other compounds, particularly those with an amino-
Table 9. Summary of Eﬃcacy of 15 and Minocycline Against
Wolbachia in the Adult B. malayi SCID Mouse Model
dosing duration
28 days 14 days 7 days
15
25 mg/kg, BID 45.5 16.6 13.4
Minocycline
25 mg/kg, BID 98.2
Table 10. Eﬃcacy of 15 and Doxycycline against Wolbachia
in the Adult L. sigmodontis Mouse Model
dosing duration
28 days 14 days
15
50 mg/kg, BID 99.2 99.7
Doxycycline
40 mg/kg, BID 99.9 99.9
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methyl substituent on the benzoxaborole core (e.g. 20)
exhibited better metabolic stability (Clint = 6 μL/min/mg),
they were compromised by very low permeability (Papp < 0.1 ×
10−6 cm/s).
When 15 was dosed to mice by the intravenous route (5
mg/kg), we were encouraged by the relatively low clearance
(Clint = 505 mL/hr/kg), good exposure (AUC0−24h = 8.85 h/
μg/mL). Following oral administration (10 mg/kg), 15
exhibited good exposure (AUC0−24h = 14.0 h/μg/mL) and
bioavailability (F = 61%). Additional PK studies at higher oral
doses demonstrated that exposure increased with dose, though
not dose proportionally, to very high levels (AUC0−24h = 58.7
h/μg/mL at 400 mg/kg). In addition to the parent compound,
we also tracked the major (and active) metabolite of 15 (15a,
IC50 = 193 nM) where hydroxylation at C(2) of the
pleuromutilin core had occurred, as this represented about
10−15% of the parent dose at most time points. Metabolism of
pleuromutilins at this position of the core is well
precedented.48,49
Based on these observations, 15 was selected for evaluation
in several in vivo models that had been established for
evaluation of anti-Wolbachia compounds in mice. In the ﬁrst
study, we found that 15, when dosed orally at 25 mg/kg, BID,
to SCID mice infected with larval stage B. malayi, eﬃcacy
(deﬁned as >99% reduction in Wolbachia load in worms) was
achieved following 14 days of dosing; 7 days dosing did not
achieve full eﬃcacy. In a second B. malayi model employing
worms that had been allowed to mature to the adult stage, we
were disappointed to ﬁnd that 15 did not demonstrate
measureable eﬃcacy when dosed at 25 mg/kg, BID for 28
days. More encouraging data were obtained in the L.
sigmodontis BALB/c mouse model, where 15 was found to
show excellent eﬃcacy (>99% Wolbachia depletion) when
dosed at 50 mg/kg, BID for 14 or 28 days. Additional in vivo
studies to address this hypothesis are ongoing and will be
reported in due course.
In conclusion, exploration of a series of pleuromutilin
derivatives incorporating a novel boron-containing heterocycle
linked to C(14) of pleuromutilin core as anti-Wolbachia agents
has resulted in the identiﬁcation of 15 as a potential preclinical
candidate. SAR developed in this program has demonstrated
that optimal activity was obtained by direct linkage of the
benzoxaborole to the pleuromutilin core via C(6) of the
benzoxaborole, and that small substituents on the benzox-
aborole ring system had an impact on potency and
pharmacokinetic properties. Good-to-excellent exposure fol-
lowing oral administration of 15 to mice was achieved, and this
translated into high levels of Wolbachia depletion in several in
vivo models. We were encouraged by the eﬃcacy of 15 in these
models, prompting more extensive evaluation of this
compound, both alone and in combination with other
known anti-Wolbachia drugs. The outcome of these studies
will be reported in due course.
■ EXPERIMENTAL SECTION
General. All chemicals were purchased from commercial suppliers
and used as received. 1H NMR spectra were recorded on a Bruker
AVANCE 400 spectrometer. Chemical shifts are expressed in δ ppm
referenced to an internal tetramethylsilane (δ = 0 ppm) standard.
Abbreviations used in describing peak signals are br = broad, s =
singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet,
m = multiplet. All ﬁnal compounds were puriﬁed to have purity higher
than 95% by reverse phase high-performance liquid chromatography
(HPLC), supercritical ﬂuid chromatography, normal phase ﬂash
chromatography, or crystallization. Preparative HPLC was accom-
plished using a Luna C18 250 × 30 mm, 10 μm column. The purity
was assessed by reverse phase HPLC with a gradient of 5−95%
acetonitrile in water (with or without acid modiﬁer) and monitored
by a diode array ultraviolet detector at 220 and 254 nm. Low-
resolution mass spectra were recorded on a liquid chromatography−
mass spectrometer in electrospray positive (ESI+) or negative (ESI−)
modes.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-(Tosyloxy)acetate (6). p-Toluenesulfonyl chloride
(19.1 g, 0.1 mol) in 1,2-dichloroethane (100 mL) was slowly added to
a mixture of (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-
yl 2-hydroxyacetate (35.4 g, 0.1 mol), triethylamine (12.0 g, 0.1 mol),
and pyridine (1 mL) in 1,2-dichloroethane (100 mL). The mixture
was stirred at 10−15 °C for 20 h, washed with water (3 × 100 mL),
and then concentrated to dryness. Puriﬁcation was achieved by
recrystallization from dichloromethane/petroleum ether (1:100) to
aﬀord (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-
3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-
(tosyloxy)acetate 6 as a white solid (45.0 g, yield 90.0%). 1H NMR
(DMSO-d6, 400 MHz): δ 7.80 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.0
Hz, 1H), 6.05 (dd, J = 17.8, 11.2 Hz, 1H), 5.53 (d, J = 8.4 Hz, 1H),
5.09−4.96 (m, 2H), 4.81−4.59 (m, 2H), 3.40 (d, J = 5.6 Hz, 1H),
2.41 (s, 2H), 2.39 (br s, 1H), 2.24−1.95 (m, 5H), 1.75−1.41 (m,
4H), 1.30 (s, 4H), 1.27−1.18 (m, 4H), 1.03 (s, 3H), 0.99−0.92 (m,
2H), 0.81 (d, J = 7.2 Hz, 3H), 0.50 (d, J = 7.2 Hz, 3H).
Preparation of (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-
4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-
propanocyclopenta[8]annulen-5-yl 2-Iodoacetate (7). To a
solution of 6 (51.5 g, 96.7 mmol, 1.0 equiv) in acetonitrile (600.0
mL) was added sodium iodide (87.0 g, 580.1 mmol, 6.0 equiv). The
mixture was stirred at 90 °C for 16 h at which time HPLC indicated
the reaction was completed. The reaction mixture was concentrated
under reduced pressure to remove acetonitrile. The residue was
diluted with H2O (500 mL) and extracted with dichloromethane (3 ×
500 mL). The combined organic layers were concentrated under
reduced pressure to give a residue. The residue was washed with
petroleum ether (200 mL). (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hy-
droxy-4,7 ,9 ,12-tetramethyl -3-oxo-7-v inyldecahydro-4 ,9a-
propanocyclopenta[8]annulen-5-yl 2-iodoacetate 7 (40.0 g, 81.9
mmol, 84.7% yield) was obtained as a yellow solid. 1H NMR
(DMSO-d6, 400 MHz): δ 6.11 (dd, J = 11.2, 17.9 Hz, 1H), 5.52 (d, J
= 7.9 Hz, 1H), 5.13−5.01 (m, 2H), 4.55 (d, J = 5.7 Hz, 1H), 3.82−
3.75 (m, 1H), 3.73−3.66 (m, 1H), 3.43 (t, J = 5.3 Hz, 1H), 2.45−
2.39 (m, 1H), 2.25−2.00 (m, 4H), 1.72−1.57 (m, 2H), 1.53−1.21
(m, 9H), 1.11−0.97 (m, 4H), 0.83 (d, J = 6.6 Hz, 3H), 0.64 (d, J =
7.1 Hz, 3H).
Method A. Use of Pleuromutilin Tosylate 6. Preparation of
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetramethyl-
3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-
5-yl 2-((1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-
oxy)acetate (8). A solution of 6 (1.8 g, 3.3 mmol), benzo[c][1,2]
oxaborole-1,6(3H)-diol (0.5 g, 3.3 mmol), and K2CO3 (0.7 g, 5.0
mmol) in 20 mL of DMF was heated to 50 °C overnight, at which
time LC/MS indicated the reaction was completed. Water was added
and the mixture was adjusted to pH < 4 with 2 N HCl. The solid was
ﬁltered and the crude product was puriﬁed by prep HPLC to give
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-
7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl2-((1-hy-
droxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy) acetate 8 (1.0 g,
yield 57.0%). 1H NMR (DMSO-d6, 400 MHz): δ 7.30 (d, J = 8.4 Hz,
1H), 7.19 (d, J = 2.0 Hz, 1H), 7.04 (dd, J = 8.4, 2.4 Hz, 1H) 6.10 (dd,
J = 17.6, 11.2 Hz, 1H), 5.59 (d, J = 8.4 Hz, 1H), 5.11−4.97 (m, 2H),
4.91 (s, 2H), 4.76−4.63 (m, 2H), 3.41 (d, J = 5.6 Hz, 1H), 2.40 (br s,
1H), 2.26−1.99 (m, 4H), 1.72−1.43 (m, 4H), 1.38 (d, J = 13.2 Hz,
1H), 1.34 (s, 3H), 1.29−1.15 (m, 4H), 1.03 (s, 3H), 1.01 (br s, 1H),
0.81 (d, J = 6.8 Hz, 3H), 0.63 (d, J = 6.8 Hz, 3H).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
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annulen-5-yl 2-((1-Hydroxy-3-methyl-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)oxy)acetate (9). Prepared from 6 by Method
A. 1H NMR (DMSO-d6, 400 MHz): δ 9.00 (s, 1H), 7.28 (d, J = 9.2
Hz, 1H), 7.15 (d, J = 2.4 Hz, 1H), 7.02 (d, J = 8.0 Hz, 1H), 6.09 (dd,
J = 17.6, 11.4 Hz, 1H), 5.59 (d, J = 8.0 Hz, 1H), 5.15−4.98 (m, 3H),
4.72−4.62 (m, 2H), 4.51 (d, J = 6.0 Hz, 1H), 3.40 (m, 1H), 2.40 (s,
1H), 2.26−1.98 (m, 4H), 1.67−1.26 (m, 14H), 1.07−1.01 (m, 3H),
0.81 (d, J = 6.8 Hz, 3H), 0.63 (d, J = 6.8 Hz, 3H). MS (ESI): mass
calcd for C30H41BO7, 524.3; m/z: found, 523.2 [M − 1]−. HPLC:
93.3% (220 nm), 100% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((1-Hydroxy-4-methyl-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)oxy)acetate (10). Prepared from 6 by Method
A. 1H NMR (DMSO-d6, 400 MHz): δ 7.02 (d, J = 1.76 Hz, 1H), 6.83
(d, J = 1.8 Hz, 1H), 6.10 (dd, J = 17.6, 11.2 Hz, 1H), 5.60 (d, J = 8.4
Hz, 1H), 5.12−4.96 (m, 2H), 4.87 (s, 2H), 4.75−4.60 (m, 2H), 2.41
(br s, 1H), 2.17 (s, 3H), 2.00−2.13 (m, 5H), 1.72−1.55 (m, 2H),
1.54−1.39 (m, 2H), 1.35 (s, 3H), 1.32−1.20 (m, 3H), 1.04 (m, 4H),
0.82 (d, J = 6.4 Hz, 3H), 0.64 (d, J = 7.2 Hz, 3H). MS: 523 (M − 1)−.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((1-Hydroxy-5-methyl-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)oxy)acetate (11). Prepared from 6 by Method
A. 1H NMR (DMSO-d6, 400 MHz): δ 8.93 (br s, 1H), 7.19 (s, 1H),
7.09 (s, 1H), 6.08 (dd, J = 17.6, 11.2 Hz, 1H), 5.59 (d, J = 8.0 Hz,
1H), 5.12−4.95 (m, 2H), 4.87 (s, 2H), 4.71 (s, 2H), 3.40 (d, J = 4.8
Hz, 1H), 2.40 (s, 1H), 2.25 (s, 3H), 2.20−1.96 (m, 3H), 1.74−1.55
(m, 2H), 1.50−1.45 (m, 1H), 1.37 (s, 3H), 1.45−1.17 (m, 6H),
1.10−0.94 (m, 4H), 0.82 (d, J = 6.4 Hz, 3H), 0.62 (d, J = 6.4 Hz,
3H). MS: 523 (M − 1)−.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((1-Hydroxy-7-methyl-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)oxy)acetate (12). Prepared from 6 by Method
A. 1H NMR (DMSO-d6, 400 MHz): δ 7.09 (d, J = 8.0 Hz, 1H), 6.95
(d, J = 8.0 Hz, 1H), 6.11 (dd, J = 17.6, 11.2 Hz, 1H), 5.61 (d, J = 8.0
Hz, 1H), 5.09−4.98 (m, 2H), 4.87 (s, 2H), 4.72 (d, J = 2.0 Hz, 2H),
3.41 (d, J = 5.6 Hz, 1H), 2.36 (s, 1H), 2.33 (s, 3H), 2.20−2.10 (m,
1H), 2.10−1.95 (m, 4H), 1.72−1.55 (m, 2H), 1.54−1.36 (m, 2H),
1.34 (s, 3H), 1.31−1.15 (m, 3H), 1.03 (s, 4H), 0.82 (d, J = 6.8 Hz,
3H), 0.63 (d, J = 6.8 Hz, 3H). MS: 523 (M − 1)−.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((4-Fluoro-1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)oxy)acetate (13). Prepared from 6 by Method
A. 1H NMR (DMSO-d6, 400 MHz): δ 9.29−9.24 (br s,1H), 7.08 (s,
1H), 6.93 (d, J = 11.2 Hz, 1H), 6.15−6.05 (m, 1H), 5.60−5.56 (d, J =
8.8 Hz, 1H), 5.05−4.99 (m, 4H), 4.77−4.75 (d, J = 8.0 Hz, 2H), 2.41
(s, 1H), 2.41−2.04 (m, 4H), 1.63−1.41 (m, 4H), 1.33−1.28 (m, 7H),
1.04−0.85 (m, 4H), 0.81 (d, J = 6.4 Hz, 3H), 0.63 (d, J = 6.4 Hz,
3H). MS (ESI): mass calcd for C29H38BFO7, 528.27; m/z: found,
527.2 [M − 1]−. HPLC: 96.0% (220 nm), 69.6% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((5-Fluoro-1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)oxy)acetate (14). Prepared from 6 by Method
A. 1H NMR (DMSO-d6, 400 MHz): δ 9.10 (s, 1H), 7.35−7.26 (m,
2H), 6.08 (dd, J = 18.0, 11.2 Hz, 1H), 5.58 (d, J = 7.6 Hz, 1H), 5.09−
4.96 (m, 2H), 4.90 (s, 2H), 4.85−4.74 (m, 2H), 4.52 (d, J = 6.0 Hz,
1H), 3.43−3.38 (m, 1H), 2.41 (s, 1H), 2.25−1.96 (m, 6H), 1.73−
1.20 (m, 9H), 1.03 (s, 3H), 0.81 (d, J = 6.8 Hz, 3H), 0.61 (d, J = 6.8
Hz, 3H). MS: 527 (M − 1)−.
Method B. Use of Pleuromutilin Tosylate 7. Preparation of
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetramethyl-
3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-
5-yl 2-((7-Fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]-
oxaborol-6-yl)oxy)acetate (15). To a solution of 7-ﬂuorobenzo-
[c][1,2]oxaborole-1,6(3H)-diol 80 (5.0 g, 29.77 mmol, 1.0 equiv) and
7 (18.9 g, 38.71 mmol, 1.3 equiv) in DMSO (60.00 mL) was added
Na2CO3 (9.5 g, 89.32 mmol, 3.0 equiv). The mixture was stirred at 35
°C for 14 h under a nitrogen atmosphere, after which time HPLC
indicated that starting material was consumed completely. The
reaction mixture was quenched by addition H2O (200 mL) at 0 °C
and then was adjusted to pH = 7 and then ﬁltered to give a crude
product. Four batches were combined together, and the crude
product was puriﬁed by prep HPLC, then removed the acetonitrile,
resulting aqueous phase was extracted by dichloromethane (3 × 1500
mL). The combined organic layers were concentrated under reduced
pressure to give the product as a light yellow solid. This product was
dissolved in dichloromethane, and then MTBE and petroleum ether
was added until the product precipitated. The suspension was ﬁltered
and the ﬁltrate was concentrated under reduced pressure to give
additional product as a white solid. (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-
Hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-
propanocyclopenta[8]annulen-5-yl 2-((7-ﬂuoro-1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate 15 (15.0 g, 28.2
mmol, 24% yield, 99.0% purity) was obtained as a white solid. 1H
NMR (DMSO-d6, 400 MHz): δ 9.26 (br s, 1H), 7.25−7.17 (m, 1H),
7.09 (d, J = 7.9 Hz, 1H), 6.11 (dd, J = 11.2, 17.9 Hz, 1H), 5.60 (d, J =
7.9 Hz, 1H), 5.10−4.98 (m, 2H), 4.92 (s, 2H), 4.86−4.74 (m, 2H),
4.52 (br s, 1H), 3.41 (br s, 1H), 2.41 (br s, 1H), 2.25−2.01 (m, 4H),
1.70−1.57 (m, 2H), 1.48−1.20 (m, 8H), 1.15−0.91 (m, 4H), 0.82 (d,
J = 6.6 Hz, 3H), 0.62 (d, J = 7.1 Hz, 3H). MS (ESI): mass calcd for
C29H38BFO7, 528.27; m/z: found, 527.3 [M − H]−. HPLC: 99.0%
(220 nm), 100.0% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((7-Chloro-1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)oxy)acetate (16). Prepared from 6 by Method
A. 1H NMR (400 MHz, DMSO-d6): δ 9.06 (s, 1H), 7.18 (d, J = 8 Hz,
1H), 7.07 (d, J = 8.4 Hz, 1H), 6.04 (dd, J = 17.6, 11.2 Hz, 1H), 5.53
(d, J = 7.2 Hz, 1H), 5.02 (m, 2H), 4.84 (s, 2H), 4.79 (s, 2H), 4.49 (d,
J = 6.4 Hz, 1H), 3.35 (m, 1H), 2.35 (s, 1H), 2.11−1.96 (m, 4H),
1.61−1.17 (m, 10H), 0.98−0.93 (m, 4H), 0.74 (d, J = 6.8 Hz, 3H),
0.58 (d, J = 6.8 Hz, 3H). MS (ESI): mass calcd For C29H38BO7Cl
544.87; m/z: found, 543.2 [M − H]−. HPLC: 100% (220 nm), 100%
(254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((1-Hydroxy-7-methoxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)oxy)acetate (17). Prepared from 6 by Method
A. 1H NMR (DMSO-d6, 400 MHz): δ 9.20−8.94 (m, 1H), 7.03 (d, J
= 8.4 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.12 (dd, J = 11.5, 17.6 Hz,
1H), 5.61 (d, J = 8.4 Hz, 1H), 5.10−5.00 (m, 2H), 4.89 (s, 2H),
4.74−4.60 (m, 2H), 3.93 (s, 3H), 3.42 (d, J = 6.2 Hz, 1H), 2.41 (br s,
1H), 2.24−1.99 (m, 4H), 1.71−1.20 (m, 11H), 1.12−0.94 (m, 4H),
0.82 (d, J = 7.1 Hz, 3H), 0.63 (d, J = 6.6 Hz, 3H). MS (ESI): mass
calcd for C30H41BO8, 540.3; m/z: found, 539.3 [M − 1]−. HPLC:
100% (220 nm), 100% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((5,7-Diﬂuoro-1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)oxy)acetate (18). Prepared from 6 by Method
A. 1H NMR (DMSO-d6, 400 MHz): δ 7.16 (d, J = 10.1 Hz, 1H), 6.05
(dd, J = 11.5, 17.6 Hz, 1H), 5.57 (d, J = 7.9 Hz, 1H), 4.97 (d, J = 6.6
Hz, 1H), 4.93 (s, 1H), 4.89 (s, 2H), 4.71 (d, J = 19.0 Hz, 2H), 3.36
(d, J = 6.2 Hz, 1H), 2.34 (br s, 1H), 2.20−2.09 (m, 1H), 2.08−1.94
(m, 3H), 1.67−1.51 (m, 3H), 1.41 (d, J = 17.2 Hz, 1H), 1.36−1.14
(m, 6H), 1.03−0.90 (m, 4H), 0.78 (d, J = 7.1 Hz, 3H), 0.53 (d, J =
6.6 Hz, 3H). MS (ESI): mass calcd For C29H37BF2NO7, 546.3; m/z:
found, 545.2 [M − H]−. HPLC: 97.3% (220 nm), 94.0% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-y l 2- ( (3 - (Aminomethyl ) -1-hydroxy-1 ,3-
dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate Hydrochlor-
ide (19). Prepared from 7 by Method B. 1H NMR (DMSO-d6, 400
MHz): δ 9.47 (br s, 1H), 8.13 (br s, 3H), 7.44 (d, J = 8.4 Hz, 1H),
7.28 (d, J = 2.2 Hz, 1H), 7.09 (td, J = 2.4, 8.5 Hz, 1H), 6.10 (dd, J =
11.2, 17.9 Hz, 1H), 5.60 (d, J = 8.4 Hz, 1H), 5.28 (dd, J = 2.6, 9.3 Hz,
1H), 5.12−4.96 (m, 2H), 4.80−4.64 (m, 2H), 4.62−4.48 (m, 1H),
3.42 (d, J = 5.7 Hz, 2H), 2.78−2.63 (m, 1H), 2.42 (br s, 1H), 2.26−
2.00 (m, 4H), 1.73−1.18 (m, 7H), 1.05 (s, 2H), 0.89−0.78 (m, 5H),
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0.63 (d, J = 7.2 Hz, 3H). MS (ESI): mass calcd for C30H42BNO7,
539.31; m/z: found, 540.1 [M + H]+. HPLC: 99.2% (220 nm),
100.0% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-y l 2- ( (4- (Aminomethyl ) -1-hydroxy-1 ,3-
dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate Hydrochlor-
ide (20). Prepared from 7 by Method B. 1H NMR (DMSO-d6, 400
MHz): δ 9.19 (s, 1H), 8.30 (br s, 3H), 7.26−7.17 (m, 2H), 6.11 (dd,
J = 11.2, 17.9 Hz, 1H), 5.62 (d, J = 8.8 Hz, 1H), 5.15−4.95 (m, 4H),
4.79−4.65 (m, 2H), 4.55 (br s,1H), 3.93 (d, J = 5.3 Hz, 2H), 3.43 (br
s, 2H), 2.44 (d, J = 7.9 Hz, 1H), 2.26−2.01 (m, 4H), 1.73−1.19 (m,
10H), 1.12−0.94 (m, 4H), 0.82 (d, J = 7.1 Hz, 3H), 0.65 (d, J = 7.1
Hz, 3H). MS (ESI): mass calcd for C30H43BClNO7, 575.3; m/z:
found, 540.4 [M + H]+. HPLC: 96.1% (220 nm), 91.0% (weak
absorption at 254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((3-(Aminomethyl)-7-chloro-1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate Hydrochlor-
ide (21). Prepared from 7 by Method B. 1H NMR (400 MHz,
DMSO-d6): δ 9.31 (s, 1H), 8.13 (s, 3H), 7.40 (d, J = 8.4 Hz, 1H),
7.18 (t, J = 8.4 Hz, 1H), 6.15−6.08 (m, 1H), 5.60 (d, J = 7.2 Hz, 1H),
5.29 (d, J = 8.0 Hz, 1H), 5.14−4.57 (m, 5H), 3.47−3.38 (m, 3H),
2.87 (b, 1H), 2.42 (s, 1H), 2.23−2.02 (m, 4H), 1.67−1.05 (m, 14H),
0.82 (d, J = 6.8 Hz, 3H), 0.63 (d, J = 6.8 Hz, 3H). HPLC purity:
100% (220 nm); MS (ESI): mass calcd for C30H41BClNO7, 573.27;
m/z: found, 574.2 [M + H]+.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((3-(Aminomethyl)-7-ﬂuoro-1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate Hydrochlor-
ide (22). Prepared from 7 by Method B. 1H NMR (DMSO-d6, 400
MHz): δ 9.51 (br s, 1H), 8.14 (br s, 3H), 7.27−7.22 (m, 2H), 6.11
(dd, J = 10.8, 18.0 Hz, 1H), 5.60 (d, J = 7.6 Hz, 1H), 5.30 (d, J = 8.8
Hz, 1H), 5.06 (d, J = 18.0 Hz, 1H), 5.03 (d, J = 10.8 Hz, 1H), 4.86−
4.82 (m, 2H), 2.84−2.82 (m, 2H), 2.41 (s, 1H), 2.18−2.05 (m, 4H),
1.64−1.20 (m, 9H), 1.09−0.94 (m, 4H), 0.83−0.79 (d, J = 6.8 Hz,
3H), 0.63 (d, J = 6.8 Hz, 3H). MS (ESI): mass calcd for
C30H42BClFNO7, 593.3; m/z: found, 558.0(M + H)
+. HPLC:
99.0% (220 nm), 96.3% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((4-(Aminomethyl)-7-chloro-1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate (23). Prepared
from 7 by Method B. 1H NMR (400 MHz, DMSO-d6): δ 9.04 (s,
1H), 7.17 (s, 1H), 6.16−6.13 (m, 1H), 5.61 (d, J = 8.0 Hz, 1H),
5.11−5.01 (m, 2H), 4.97 (s, 2H), 4.822 (d, J = 4.0 Hz, 2H), 4.54 (d, J
= 6.0 Hz, 1H), 4.46−4.44 (m, 2H), 3.62 (s, 2H), 2.43 (s, 1H), 2.23−
2.04 (m, 4H), 1.68−0.97 (m, 14H), 0.81 (d, J = 7.2 Hz, 3H), 0.66 (d,
J = 6.8 Hz, 3H). HPLC purity: 100% (214 nm); MS (ESI): mass
calcd For C30H41BClNO7, 573.27; m/z: found, 573.8 [M + H]
+.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((1-Hydroxy-3,3-dimethyl-1,3-dihydrobenzo-
[c][1,2]oxaborol-6-yl)oxy)acetate (24). Prepared from 7 by
Method B. 1H NMR (DMSO-d6, 400 MHz): δ 8.92 (s, 1H), 7.29
(d, J = 8.4 Hz, 1H), 7.11 (d, J = 2.4 Hz, 1H), 7.00 (dd, J = 8.4, 2.4 Hz,
1H), 6.09 (dd, J = 17.6, 11.2 Hz, 1H), 5.59 (d, J = 8.4 Hz, 1H), 5.08−
4.95 (m, 2H), 4.75−4.61 (m, 2H), 4.51 (d, J = 6.0 Hz, 1H), 3.45−
3.38 (m, 1H), 2.40 (s, 1H), 2.25−1.98 (m, 5H), 1.73−1.55 (m, 3H),
1.52−1.15 (m, 12H), 1.08−0.98 (m, 4H), 0.81 (d, J = 7.0 Hz, 3H),
0.62 (d, J = 6.8 Hz, 3H). MS (ESI): mass calcd for C31H43BO73,
538.3; m/z: found, 537.2 [M − 1]−. HPLC: 99.3% (220 nm), 100%
(254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl (1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-
yl)glycinate (25). Prepared from 7 by Method B. 1H NMR (DMSO-
d6, 400 MHz): δ 7.09 (d, J = 8.4 Hz, 1H), 6.83 (br s, 1H), 6.72 (d, J =
8.4 Hz, 1H), 6.12−5.96 (m, 1H), 5.53 (d, J = 8.0 Hz, 1H), 5.07−4.90
(m, 2H), 4.87−4.77 (m, 1H), 3.78 (d, J = 5.2 Hz, 2H), 3.37 (d, J =
5.2 Hz, 1H), 2.33 (br s, 1H), 2.22−2.12 (m, 1H), 2.10−1.91 (m, 3H),
1.70−1.52 (m, 3H), 1.43 (br s, 2H), 1.37−1.15 (m, 8H), 1.06−0.89
(m, 5H), 0.79 (d, J = 6.4 Hz, 3H), 0.61 (d, J = 6.4 Hz, 3H). MS
(ESI): mass calcd for C29H41BClNO6, 545.27; m/z: found, 508.3 [M
− H]−. HPLC: 100.0% (220 nm), 100.0% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl (3-(Aminomethyl)-1-hydroxy-1,3-dihydrobenzo-
[c][1,2]oxaborol-6-yl)glycinate (26). Prepared from 7 and 6-
amino-1-hydroxy-3-nitromethyl-1,3-dihydrobenzo[c][1,2]oxaborole
by Method B and reduction of the nitromethyl intermediate by
hydrogenation. 1H NMR (DMSO-d6, 400 MHz): δ 8.12 (br s, 2H),
7.20 (d, J = 7.9 Hz, 1H), 6.91 (br s, 1H), 6.73 (dd, J = 1.6, 8.4 Hz,
1H), 6.08 (dd, J = 11.2, 17.6 Hz, 1H), 5.55 (d, J = 8.0 Hz, 1H), 5.19
(d, J = 7.6 Hz, 1H), 5.04 (d, J = 19.2 Hz, 1H), 4.95 (d, J = 11.2 Hz,
1H), 3.80 (d, J = 13.2 Hz, 2H), 3.41 (d, J = 5.6 Hz, 2H), 2.39 (br s,
1H), 2.22−2.14 (m, 1H), 2.12−1.98 (m, 3H), 1.69−1.57 (m, 2H),
1.54−1.39 (m, 2H), 1.38−1.32 (m, 5H), 1.31−1.18 (m, 3H), 1.08−
0.94 (m, 4H), 0.81 (d, J = 6.4 Hz, 3H), 0.64 (d, J = 6.4 Hz, 3H). MS
(ESI): mass calcd For C30H44BClN2O6, 574.9; m/z: found, 539.5 [M
+ H]+. HPLC: 98.9% (220 nm), 100.0% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl (4-(Aminomethyl)-1-hydroxy-1,3-dihydrobenzo-
[c][1,2]oxaborol-6-yl)glycinate (27). Prepared from 7 and 6-
amino-4-(t-butyloxycarbonyl)aminomethyl-1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborole by Method B and deprotection of the
(t-butyloxycarbonyl)aminomethyl intermediate with triﬂuoracetic
acid. 1H NMR (400 MHz, DMSO-d6): δ 8.84 (s, 1H), 6.71 (m,
2H), 6.09 (m, 1H), 5.92 (m, 1H), 5.54 (m, 1H), 4.89−5.07 (m, 4H),
4.52 (d, 1H), 3.78 (m, 2H), 3.58 (s, 4H), 3.41 (m, 1H), 2.41 (m,
1H), 2.02−2.09 (m, 5H), 1.34−1.67 (m, 7H), 1.24−1.28 (m, 4H),
1.01 (s, 4H). HPLC purity: 98.4% (214 nm), 100% (254 nm); MS
(ESI): mass calcd for C30H43BN2O6, 538.32; m/z: found, 539.2 [M +
H]+.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl (5-(Aminomethyl)-1-hydroxy-1,3-dihydrobenzo-
[c][1,2]oxaborol-6-yl)glycinate (28). Prepared from 7 and 6-
amino-5-( t-butyloxycarbonyl)aminomethyl-1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborole by Method B and deprotection of the
(t-butyloxycarbonyl)aminomethyl intermediate with triﬂuoracetic
acid. 1H NMR (400 MHz, DMSO-d6): δ 8.98 (s, 1H), 7.22 (s,
1H), 6.82 (s, 1H), 6.00−6.08 (dd, 1H), 5.56 (s, 1H), 5.53−5.57 (d,
1H), 4.88−5.02 (m, 3H), 4.43−4.54 (m, 1H), 3.85−4.04 (m, 2H),
3.04 (s, 1H), 2.07−2.50 (m, 7H), 1.31−1.66 (m, 13H), 1.05−1.24
(m, 4H), 0.50−0.60 (m, 3H), 0.22−0.37 (m, 3H). HPLC purity:
100% (214 nm), 100% (254 nm); MS (ESI): mass calcd for
C30H43BN2O6, 538.32; m/z: found, 539.3 [M + H]
+.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl (7-(Aminomethyl)-1-hydroxy-1,3-dihydrobenzo-
[c][1,2]oxaborol-6-yl)glycinate (29). Prepared from 7 and 6-
amino-7-( t-butyloxycarbonyl)aminomethyl-1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborole by Method B and deprotection of the
(t-butyloxycarbonyl)aminomethyl intermediate with triﬂuoracetic
acid. 1H NMR (500 MHz, added one drop of con. HCl, DMSO-
d6): δ 8.2 (s, 3H), 7.19 (d, J = 8.0 Hz, 1H), 6.70 (d, J = 8.5 Hz, 1H),
6.08 (m, 1H), 5.55 (d, J = 8.5 Hz, 2H), 4.89 (s, 4H), 4.21 (m, 2H),
3.91 (m, 2H), 3.41 (m, 1H), 2.41 (s, 1H), 2.00−2.22 (m, 4H), 1.58−
1.66 (m, 2H), 1.48 (m, 1H), 1.24−1.39 (m, 7H), 0.97−1.03 (m, 4H),
0.80 (d, J = 7.5 Hz, 3H), 0.64 (d, J = 7.0 Hz, 3H). HPLC purity:
100% (214 nm), 100% (254 nm); MS (ESI): mass calcd for
C30H43BN2O6, 538.32; m/z: found, 539.4 [M + H]
+.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl (1-Hydroxy-3,3-dimethyl-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)glycinate (30). Prepared from 7 by Method
B. 1H NMR (400 MHz, DMSO-d6): δ 8.72 (s, 1H), 7.06 (d, J = 8.4
Hz, 1H), 6.75−6.65 (m, 2H), 6.11−6.03 (m, 2H), 5.55 (d, J = 8.4 Hz,
1H), 5.04−4.93 (m, 2H), 4.50 (d, J = 6 Hz, 1H), 3.83−3.75 (m, 2H),
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3.40 (t, J = 7.8 Hz, 1H), 2.39 (s, 1H), 1.48−1.21 (m, 21H), 0.80 (d, J
= 6.8 Hz, 3H), 0.63 (d, J = 8.8 Hz, 3H). MS (ESI): mass calcd For
C31H44BNO6, 537.33; m/z: found, 538.4 [M + H]
+. HPLC: 98.8%
(220 nm), 99.5% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl (5-Fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]-
oxaborol-6-yl)glycinate (31). Prepared from 7 by Method B. 1H
NMR (DMSO-d6, 400 MHz): δ 8.88 (s, 1H), 7.11−7.09 (d, J = 8.0
Hz, 1H), 6.88−6.86 (d, J = 8.0 Hz, 1H), 6.09−6.04 (m, 1H), 5.75 (s,
1H), 5.54−5.42 (d, J = 8.0 Hz, 1H), 5.05−5.01 (m, 1H), 4.95−4.93
(m, 1H), 4.83 (s, 2H), 3.86−3.83 (m, 2H), 2.37−2.17 (m, 1H),
2.14−2.08 (m, 2H), 2.06−2.01 (m, 3H),1.66−1.62 (m, 3H),1.59−
1.32 (m, 5H), 1.24−1.21 (m, 4H), 1.00 (s, 3H), 0.81−0.79 (d, J = 8.0
Hz, 3H), 0.62−0.61 (d, J = 4.0 Hz, 3H).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl (7-Fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]-
oxaborol-6-yl)glycinate (32). Prepared from 7 by Method B. 1H
NMR (DMSO-d6, 400 MHz): δ 9.10 (s, 1H), 6.94 (d, J = 7.9 Hz,
1H), 6.73 (t, J = 8.2 Hz, 1H), 6.09 (dd, J = 11.0, 17.6 Hz, 1H), 5.63
(br s, 1H), 5.55 (d, J = 7.9 Hz, 1H), 5.08−4.96 (m, 2H), 4.86 (s, 2H),
4.49 (d, J = 6.2 Hz, 1H), 3.91−3.81 (m, 2H), 3.38 (s, 1H), 2.38 (br s,
1H), 2.23−2.12 (m, 1H), 2.11−1.97 (m, 3H), 1.69−1.56 (m, 2H),
1.52−1.42 (m, 2H), 1.32 (s, 3H), 1.29−1.16 (m, 3H), 1.05−0.96 (m,
3H), 0.80 (d, J = 7.1 Hz, 3H), 0.63 (d, J = 6.6 Hz, 3H). MS (ESI):
mass calcd For C29H39BFNO6, 527.4; m/z: found, 526.3 [M − H]−.
HPLC: 96.7% (220 nm), 100.00% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((1-Hydroxy-1,3-dihydrobenzo[c][1,2]-
oxaborol-6-yl)thio)acetate (33). Prepared from 7 by Method B.
1H NMR (DMSO-d6, 400 MHz): δ 9.18 (s, 1H), 7.72 (s, 1H), 7.49
(dd, J = 1.2, 8.0 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 6.03−5.94 (m,
1H), 5.47 (d, J = 8.8 Hz, 1H), 4.94 (s, 2H), 4.90 (d, J = 4.4 Hz, 1H),
4.47 (d, J = 6.0 Hz, 1H), 3.79 (q, J = 16.0 Hz, 2H), 3.37 (s, 1H),
2.37−2.31 (m, 1H), 2.22−1.87 (m, 4H), 1.68−1.55 (m, 2H), 1.50−
1.14 (m, 7H), 1.08−0.93 (m, 6H), 0.79 (d, J = 6.4 Hz, 3H), 0.55 (d, J
= 6.4 Hz, 3H). MS (ESI): mass calcd for C29H39BO6S 526.26; m/z:
found, 549.3 [M + Na]+. HPLC: 96.5% (220 nm), 96.8% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((7-Fluoro-1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)thio)acetate (34). Prepared from 7 by Method
B. 1H NMR (DMSO-d6, 400 MHz): δ 9.34 (s, 1H), 7.61 (t, J = 7.2
Hz, 1H), 7.22 (d, J = 8.0 Hz, 1H), 6.04−5.94 (m, 1H), 5.46 (d, J =
8.0 Hz, 1H), 5.00−4.88 (m, 4H), 4.50 (d, J = 6.0 Hz, 1H), 3.88−3.71
(m, 2H), 3.41−3.36 (m, 2H), 2.38−2.35 (m, 1H), 2.24−1.87 (m,
4H), 1.69−1.55 (m, 2H), 1.50−1.40 (m, 1H), 1.29 (s, 5H), 1.06−
0.93 (m, 5H), 0.80 (d, J = 6.8 Hz, 3H), 0.55 (d, J = 6.8 Hz, 3H). MS
(ESI): mass calcd for C29H38BFO6S 544.25; m/z: found, 543.2 [M −
H]−. HPLC: 100% (220 nm), 100% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl ((1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-
6-yl)methyl)glycinate (35). Prepared from 7 by Method B. 1H
NMR (400 M Hz, DMSO-d6): δ 0.60 (d, J = 7.2 Hz, 3H), 0.78 (d, J =
6.8 Hz, 3H), 0.97 (br s, 1H), 1.02 (d, 3H), 1.24 (d, 3H), 1.25 (s, 1H),
1.4, (m, 3H), 1.61−1.9 (m, 3H), 2.02 (m, 2H), 2.07 (m, 2H), 2.4 (s,
2H), 3.8 (m, 2H), 4.1 (m, 2H), 4.4 (br, s, 1H), 5.0−5.1 (m, 4H), 5.59
(d, J = 8.4 Hz, 1H), 6.06 (dd, J = 17.8, 11.2 Hz, 1H), 7.5 (m, 2H),
7.75 (s, 1H), 9.3 (br, s, 1H), 9.5 (br, s, 1H). MS (ESI): mass calcd
For C30H42BNO6, 523.31; m/z: found, 524.3 [M + H]
+. HPLC:
99.0% (220 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl ((1-Hydroxy-3,3-dimethyl-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)methyl)glycinate (36). Prepared from 7 by
Method B. 1H NMR (400 MHz, DMSO-d6): δ 8.96 (s, 1H), 7.57 (s,
1H), 7.38−7.32 (m, 2H), 6.24−6.17 (m, 1H), 5.62 (d, J = 8.0 Hz,
1H), 5.12−5.06 (m, 2H), 4.53 (d, J = 6.0 Hz, 1H), 3.71−3.68 (m,
2H), 3.43−3.17 (m, 3H), 2.42 (s, 2H), 2.16−2.08 (m, 4H), 1.70−
1.03 (m, 21H), 0.83 (d, J = 6.8 Hz, 3H), 0.62 (d, J = 6.8 Hz, 3H).
HPLC purity: 100% (214 nm), 100% (254 nm); MS (ESI): mass
calcd for C32H46BNO6, 551.34; m/z: found, 552.2 [M + H]
+.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((1-Hydroxy-1,3-dihydrobenzo[c][1,2]-
oxaborol-5-yl)oxy)acetate (37). Prepared from 7 by Method B.
1H NMR (400 MHz, DMSO-d6): δ 9.05 (s, 1H), 7.54 (d, J = 7.2 Hz,
1H), 6.82 (m, 2H), 6.03 (dd, J = 17.6, 11.2 Hz, 1H), 5.54 (d, J = 8.4
Hz, 1H), 5.00 (m, 2H), 4.81 (s, 2H), 4.70 (m, 2H), 4.51 (d, J = 6 Hz,
1H), 3.36 (m, 1H), 2.35 (s, 1H), 2.11−1.97 (m, 4H), 1.68−1.17 (m,
10H), 0.92 (m, 4H),0.74 (d, J = 7.2 Hz, 3H), 0.56 (d, J = 7.2 Hz,
3H). HPLC: 100% (220 nm), 100% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((6-Fluoro-1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-5-yl)oxy)acetate (38). Prepared from 7 by Method
B. 1H NMR (400 MHz, DMSO-d6): δ 9.28 (s, 1H), 7.39 (d, J = 10.4
Hz, 1H), 7.02 (d, J = 7.2 Hz, 1H), 6.03 (dd, J = 18.0, 11.2 Hz, 1H),
5.53 (d, J = 8.0 Hz, 1H), 4.96 (m, 2H), 4.81 (d, 2H), 4.78 (s, 2H),
4.50 (d, J = 6 Hz, 1H), 3.36 (m, 1H), 2.35 (s, 1H), 2.08−1.96 (m,
4H), 1.60−1.19 (m, 10H), 0.98−0.93 (m, 4H),0.74 (d, J = 6.8 Hz,
3H), 0.56 (d, J = 7.2 Hz, 3H). MS (ESI): mass calcd For C29H38BO7F
528.42; m/z: found, 527.2 [M − H]−. HPLC: 100% (220 nm), 100%
(254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((7-Fluoro-1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-5-yl)oxy)acetate (39). Prepared from 7 by Method
B. 1H NMR (400 MHz, DMSO-d6): δ 9.20 (s, 1H), 6.73 (s, 1H), 6.60
(d, J = 10 Hz, 1H), 6.03 (dd, J = 18.0, 11.2 Hz, 1H), 5.54 (d, J = 8.4
Hz, 1H), 4.97 (m, 2H), 4.84 (s, 2H), 4.75 (m, 2H), 4.51 (d, J = 6 Hz,
1H), 3.36 (m, 1H), 2.35 (s, 1H), 2.13−1.96 (m, 4H), 1.61−1.17 (m,
10H), 0.98−0.91 (m, 4H),0.75 (d, J = 7.2 Hz, 3H), 0.57 (d, J = 6.8
Hz, 3H). MS (ESI): mass calcd For C29H38BO7F 528.42; m/z: found,
586.0 [M+59-H]‑. HPLC: 100% (220 nm), 100% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((1-Hydroxy-2-(methylsulfonyl)-1,2-
dihydrobenzo[d][1,2,3]diazaborinin-7-yl)oxy)acetate (40). Pre-
pared from 7 by Method B. 1H NMR (DMSO-d6, 400 MHz): δ 8.18
(s, 1H), 8.80−8.78 (m, 1H), 8.66 (s, 1H), 7.41−7.39 (m, 1H), 6.12−
6.08 (m, 1H), 5.12−5.08 (m, 1H), 5.01−4.98 (m, 2H), 4.88−4.86
(m, 2H),3.37 (s, 5H), 2.40 (s, 1H), 2.09−2.03 (m, 4H), 1.70−1.45
(m, 3H), 1.33−1.25 (m, 8H), 1.05−0.95 (m, 4H), 0.82−0.80 (m,
3H), 0.65−0.64 (m, 3H).
(3aR,4R,5R,7S,8S,9aS,12R)-8-Hydroxy-4,7,12-trimethyl-3-
oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-
yl 2-((1-Hydroxy-2-methyl-1,2-dihydrobenzo[d][1,2,3]-
diazaborinin-7-yl)oxy)acetate (41). Prepared from 7 by Method
B. 1H NMR (DMSO-d6, 400 MHz): δ 8.31 (s, 1H), 7.90 (s, 1H), 7.76
(br s, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.28 (d, J = 7.3 Hz, 1H), 6.10
(dd, J = 10.8, 17.2 Hz, 1H), 5.60 (d, J = 7.8 Hz, 1H), 5.14−4.93 (m,
2H), 4.88−4.71 (m, 2H), 4.54 (d, J = 5.8 Hz, 1H), 3.47 (s, 2H), 3.41
(br s, 1H), 3.07 (s, 3H), 2.41 (br s, 1H), 2.26−1.95 (m, 4H), 1.73−
0.92 (m, 10H), 0.90−0.76 (m, 3H), 0.63 (d, J = 6.0 Hz, 3H). MS
(ESI): mass calcd for C30H41BN2O6, 536.3; m/z: found, 535.3 (M −
H)−. HPLC: 90.7% in 220 nm; 93.3% in 254 nm.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((2-Acetyl-1-hydroxy-1,2-dihydrobenzo[d]-
[1,2,3]diazaborinin-7-yl)oxy)acetate (42). Prepared from 7 by
Method B. 1H NMR (DMSO-d6, 400 MHz): δ 8.02 (s, 1H), 7.53 (d, J
= 8.4 Hz, 1H), 7.07−6.94 (m, 2H), 6.16−6.03 (m, 1H), 5.56 (t, J =
8.0 Hz, 1H), 5.11−4.96 (m, 2H), 4.77 (t, J = 10.0 Hz, 2H), 4.53 (d, J
= 5.8 Hz, 1H), 3.39 (d, J = 5.2 Hz, 1H), 2.36 (d, J = 1.4 Hz, 3H),
2.23−1.94 (m, 4H), 1.63 (br s, 2H), 1.49−1.09 (m, 7H), 1.00 (d, J =
17.8 Hz, 4H), 0.80 (d, J = 3.6 Hz, 3H), 0.61 (dd, J = 7.0, 12.0 Hz,
3H). MS (ESI): mass calcd for C31H41BN2O7, 564.3; m/z: found,
581.3 (M + H2O − H)‑. HPLC: 94.9% in 220 nm; 100% in 254 nm.
tert-Butyl 1-Hydroxy-7-(2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-
hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-
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propanocyclopenta[8]annulen-5-yl)oxy)-2-oxoethoxy)benzo-
[d][1,2,3]diazaborinine-2(1H)-carboxylate (43). Prepared from 7
by Method B. 1H NMR (DMSO-d6, 400 MHz): δ 8.57 (s, 1H), 8.10
(s, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.47 (br s, 1H), 7.38 (d, J = 9.2 Hz,
1H), 6.09 (dd, J = 11.0, 17.8 Hz, 1H), 5.60 (d, J = 8.6 Hz, 1H), 5.11−
4.96 (m, 2H), 4.89 (d, J = 6.0 Hz, 1H), 4.53 (d, J = 6.0 Hz, 1H), 2.41
(s, 1H), 2.26−1.96 (m, 4H), 1.65−1.58 (m, 11H), 1.53−1.21 (m,
8H), 1.13−0.97 (m, 5H), 0.81 (d, J = 6.8 Hz, 3H), 0.66 (d, J = 6.8
Hz, 3H). MS (ESI): mass calcd for C34H47BN2O8, 622.3; m/z: found,
639.4 (M + H2O − H)−. HPLC: 96.4% in 220 nm; 96.5% in 254 nm.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((1-Hydroxy-1,2-dihydrobenzo[d][1,2,3]-
diazaborinin-7-yl)oxy)acetate (44). Prepared from 43 by depro-
tection with HCl/ethyl acetate in dichloromethane. 1H NMR
(DMSO-d6, 400 MHz): δ 9.90 (s, 1H), 7.96 (s, 1H), 7.75−7.64
(m, 2H), 7.31 (d, J = 8.8 Hz, 1H), 6.09 (dd, J = 11.2, 17.8 Hz, 1H),
5.60 (d, J = 8.2 Hz, 1H), 5.13−4.95 (m, 2H), 4.89−4.74 (m, 2H),
3.41 (d, J = 5.6 Hz, 1H), 2.41 (s, 1H), 2.25−1.97 (m, 4H), 1.71−1.18
(m, 10H), 1.07−0.93 (m, 4H), 0.81 (d, J = 6.8 Hz, 3H), 0.64 (d, J =
6.8 Hz, 3H). MS (ESI): mass calcd for C29H39BN2O6, 522.3; m/z:
found, 521.3 (M − H)−. HPLC: 99.7% in 220 nm; 100% in 254 nm.
Methyl 1-Hydroxy-7-(2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hy-
droxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-
propanocyclopenta[8]annulen-5-yl)oxy)-2-oxoethoxy)benzo-
[d][1,2,3]diazaborinine-2(1H)-carboxylate (45). Prepared from 7
by Method B. 1H NMR (DMSO-d6, 400 MHz): δ 8.12 (s, 1H), 7.78
(d, J = 8.4 Hz, 1H), 7.48 (s, 1H), 7.39 (dd, J = 2.4, 8.4 Hz, 1H), 6.09
(dd, J = 11.2, 17.6 Hz, 1H), 5.60 (d, J = 7.8 Hz, 1H), 5.13−4.97 (m,
2H), 4.96−4.84 (m, 2H), 3.91 (s, 3H), 3.41 (d, J = 5.8 Hz, 1H), 2.41
(s, 1H), 2.25−1.99 (m, 4H), 1.74−1.20 (m, 10H), 1.10−0.94 (m,
4H), 0.81 (d, J = 6.8 Hz, 3H), 0.67 (d, J = 6.8 Hz, 3H). MS (ESI):
mass calcd for C31H41BN2O8, 580.3; m/z: found, 597.4 (M + H2O −
H)−. HPLC: 97.2% in 220 nm; 96.1% in 254 nm.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((1-Hydroxy-1H-benzo[d][1,2,6]oxazaborinin-
7-yl)oxy)acetate (46). Prepared from 7 by Method B. 1H NMR
(DMSO-d6, 400 MHz): δ 9.29 (s, 1H), 8.54 (s, 1H), 7.71 (d, J = 8.2
Hz, 1H), 7.49 (s, 1H), 7.37 (d, J = 6.0 Hz, 1H), 6.13−6.04 (m, 1H),
5.60 (d, J = 7.8 Hz, 1H), 5.11−4.96 (m, 2H), 4.87 (d, J = 7.2 Hz,
1H), 4.53 (d, J = 6.2 Hz, 1H), 3.41 (m, 1H), 2.41 (s, 1H), 2.05 (m,
4H), 1.71−1.44 (m, 4H), 1.40−1.20 (m, 7H), 1.04 (s, 4H), 0.81 (d, J
= 6.8 Hz, 3H), 0.65 (d, J = 7.0 Hz, 3H). MS (ESI): mass calcd for
C29H38BNO7, 523.3; m/z: found, 522.3 (M − H)−. HPLC: 97.5% in
220 nm; 94.3% in 254 nm.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((8-Fluoro-1-hydroxy-2-(methylsulfonyl)-1,2-
dihydrobenzo[d][1,2,3]diazaborinin-7-yl)oxy)acetate (47). Pre-
pared from 7 by Method B. 1H NMR (DMSO-d6, 400 MHz): δ 7.90
(s, 1H), 7.50−7.28 (m, 2H), 6.13 (m, 1H), 5.61 (s, 1H), 5.19−4.84
(m, 3H), 4.54 (s, 1H), 3.24 (s, 3H), 2.41 (s, 1H), 2.07 (m, 4H),
1.73−1.19 (m, 11H), 1.06 (m, 4H), 0.82 (d, J = 6.8 Hz, 3H), 0.65 (d,
J = 6.8 Hz, 3H). MS (ESI): mass calcd for C30H40BFN2O8S 618.3; m/
z: found, 619.2 (M + H)+. HPLC: 95.2% in 220 nm; 98.0% in 254
nm.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((8-Fluoro-1-hydroxy-2-methyl-1,2-
dihydrobenzo[d][1,2,3]diazaborinin-7-yl)oxy)acetate (48). Pre-
pared from 7 by Method B. 1H NMR (DMSO-d6, 400 MHz): δ 7.93
(d, J = 2.4 Hz, 1H), 7.54−7.44 (m, 2H), 6.10 (dd, J = 11.2, 17.6 Hz,
1H), 5.60 (d, J = 8.4 Hz, 1H), 5.10−4.98 (m, 2H), 4.94 (d, J = 3.6
Hz, 1H), 3.49 (s, 3H), 3.40 (d, J = 6.4 Hz, 1H), 2.40 (br s, 1H),
2.24−1.97 (m, 5H), 1.72−1.19 (m, 10H), 1.04 (s, 4H), 0.81 (d, J =
7.2 Hz, 3H), 0.63 (d, J = 7.2 Hz, 3H). MS (ESI): mass calcd for
C30H40BFN2O6, 554.5; m/z: found, 555.3 [M + H]
+. HPLC: 100.00%
(220 nm), 100.00% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-y l 2- ( (2-Acetyl -8-ﬂuoro-1-hydroxy-1 ,2-
dihydrobenzo[d][1,2,3]diazaborinin-7-yl)oxy)acetate (49). Pre-
pared from 7 by Method B. 1H NMR (DMSO-d6, 400 MHz): δ 8.05
(s, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.17−7.12 (m, 1H), 6.15−6.07 (m,
1H), 5.61 (d, J = 7.6 Hz, 1H), 5.13−5.00 (d, J = 3.6 Hz, 2H), 4.97−
4.83 (m, 2H), 4.56−4.50 (m, 1H), 2.44−2.38 (m, 2H), 2.23−2.00
(m, 7H), 1.70−1.19 (m, 11H), 1.05 (d, J = 3.2 Hz, 3H), 0.82 (d, J =
6.8 Hz, 3H), 0.65 (dd, J = 6.8, 17.6 Hz, 2H). MS (ESI): mass calcd
for C31H40BFN2O7, 582.5; m/z: found, 583.3(M + H)
+. HPLC:
90.0% (220 nm), 90.4% (254 nm).
Methyl 8-Fluoro-1-hydroxy-7-(2-(((3aR,4R,5R,7S,8S,9-
R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinylde-
cahydro-4,9a-propanocyclopenta[8]annulen-5-yl)oxy)-2-
oxoethoxy)benzo[d][1,2,3]diazaborinine-2(1H)-carboxylate
(50). Prepared from 7 by Method B. 1H NMR (DMSO-d6, 400
MHz): δ 8.53 (br s, 1H), 7.86 (br s, 1H), 7.48−7.29 (m, 2H), 6.11
(dd, J = 10.8, 17.6 Hz, 1H), 5.60 (d, J = 8.0 Hz, 1H), 5.13−4.99 (m,
2H), 4.98−4.86 (m, 2H), 4.54 (d, J = 6.4 Hz, 1H), 3.84 (s, 2H),
3.44−3.39 (m, 1H), 2.41 (br s, 1H), 2.29−2.00 (m, 3H), 1.73−1.19
(m, 10H), 1.11−0.94 (m, 4H), 0.81 (d, J = 6.4 Hz, 3H), 0.70−0.60
(m, 3H). MS (ESI): mass calcd for C31H40BFN2O8, 598.5; m/z:
found, 599.3(M + H)+. HPLC: 89.1% (220 nm), 100.0% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((8-Fluoro-1-hydroxy-1H-benzo[d][1,2,6]-
oxazaborinin-7-yl)oxy)acetate (51). Prepared from 7 by Method
B. 1H NMR (DMSO-d6, 400 MHz): δ 9.44−9.27 (m, 1H), 8.55 (br s,
1H), 7.54 (br s, 2H), 6.10 (dd, J = 11.2, 17.6 Hz, 1H), 5.59 (d, J = 8.8
Hz, 1H), 5.23−4.90 (m, 4H), 4.54 (br s, 1H), 2.40 (br s, 1H), 2.24−
1.97 (m, 4H), 1.72−1.19 (m, 10H), 1.10−0.94 (m, 3H), 0.81 (d, J =
6.4 Hz, 3H), 0.64 (d, J = 7.2 Hz, 3H). MS (ESI): mass calcd for
C29H37BFNO7, 541.4; m/z: found, 558.3(M + H2O − H)−. HPLC:
94.9% (220 nm), 95.8% (254 nm).
Methyl 1-Hydroxy-7-(2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hy-
droxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-
propanocyclopenta[8]annulen-5-yl)oxy)-2-oxoethoxy)-8-
methylbenzo[d][1,2,3]diazaborinine-2(1H)-carboxylate (52).
Prepared from 7 by Method B. 1H NMR (DMSO-d6, 400 MHz): δ
9.15 (br s, 1H), 8.02 (br s, 1H), 7.59 (br s, 1H), 7.33 (br s, 1H), 6.11
(dd, J = 17.6, 11.2 Hz, 1H), 5.61 (d, J = 8.4 Hz, 1H), 5.09−4.98 (m,
2H), 4.90 (s, 1H), 4.52 (d, J = 2.4 Hz, 2H), 3.90 (s, 3H), 3.41 (d, J =
5.6 Hz, 1H), 2.33 (s, 3H), 2.20−2.05 (m, 4H), 1.72−1.55 (m, 2H),
1.54−1.36 (m, 2H), 1.34 (s, 3H), 1.31−1.15 (m, 3H), 1.03 (m, 4H),
0.82 (d, J = 6.8 Hz, 3H), 0.65 (d, J = 6.8 Hz, 3H). MS (ESI): mass
calcd for C32H43BN2O8, 594.5; m/z: found, 595.4 [M + H]
+. HPLC:
93.0% (220 nm), 88.6% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((1-Hydroxy-3,4-dihydro-1H-benzo[c][1,2]-
oxaborinin-7-yl)oxy)acetate (53). Prepared from 7 by Method
B. 1H NMR (DMSO-d6, 400 MHz): δ 7.14 (s, 1H), 7.07 (d, J = 8.4
Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 6.06 (dd, J = 11.2, 17.6 Hz, 1H),
5.56 (d, J = 8.0 Hz, 1H), 5.05−4.95 (m, 3H), 4.82−4.65 (m, 2H),
3.99 (t, J = 5.6 Hz, 2H), 3.42−3.37 (m, 1H), 2.74 (t, J = 5.6 Hz, 2H),
2.38−2.32 (m, 1H), 2.23−1.98 (m, 4H), 1.72−1.19 (m, 10H), 1.08−
0.94 (m, 4H), 0.77 (d, J = 6.4 Hz, 3H), 0.60 (d, J = 6.4 Hz, 3H). MS
(ESI): mass calcd for C30H41BO7, 524.29; m/z: found, 523.2 [M −
H]−. HPLC: 99.9% (220 nm), 99.9% (254 nm).
(3aR,4R,5R,7R,8S,9R,9aS,12R)-7-Ethyl-8-hydroxy-4,7,9,12-
tetramethyl-3-oxodecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((7-Fluoro-1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)oxy)acetate (54). A suspension of 6 (500.0
mg, 938.6 μmol, 1.0 equiv) and Pd/C (300.0 mg, 938.6 μmol, 1.0
equiv) in THF (30.0 mL) was stirred at 25 °C for 12 h under 40 psi
hydrogen atmosphere. The mixture was ﬁltered and the ﬁltrate was
concentrated to give (3aR,4R,5R,7R,8S,9R,9aS,12R)-7-ethyl-8-hy-
droxy-4,7,9,12-tetramethyl-3-oxodecahydro-4,9a-propanocyclopenta-
[8]annulen-5-yl 2-(tosyloxy)acetate (500.0 mg, 902.8 μmol, 96.2%
yield, 96.5% purity) as a white foam. 1H NMR (CDCl3, 400 MHz): δ
7.83 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 5.66 (d, J = 7.9 Hz,
1H), 4.51 (s, 2H), 3.45−3.37 (m, 1H), 2.46 (s, 3H), 2.41−2.14 (m,
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4H), 2.09 (br s, 1H), 1.85−1.05 (m, 15H), 0.99−0.91 (m, 6H), 0.72
(t, J = 7.5 Hz, 3H), 0.61 (d, J = 7.1 Hz, 2H).
A solution of (3aR,4R,5R,7R,8S,9R,9aS,12R)-7-ethyl-8-hydroxy-
4,7,9,12-tetramethyl-3-oxodecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-(tosyloxy)acetate (300.0 mg, 561.1 μmol, 1.0 equiv),
80 (94.22 mg, 561.06 μmol, 1.00 equiv), and Na2CO3 (178.4 mg, 1.7
mmol, 3.0 equiv) in DMSO (15.0 mL) was heated to 30−40 °C for
12 h. Water (20 mL) was added to the mixture, white solid was
precipitated. The mixture was ﬁltered to give a crude product, which
was puriﬁed by prep HPLC to give (3aR,4R,5R,7R,8S,9R,9aS,12R)-7-
ethyl-8-hydroxy-4,7,9,12-tetramethyl-3-oxodecahydro-4,9a-
propanocyclopenta[8]annulen-5-yl 2-((7-ﬂuoro-1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate 54 (95.00 mg,
179.10 μmol, 31.92% yield, 100% purity) as a white solid. 1H NMR
(DMSO-d6, 400 MHz): δ 9.26 (s, 1H), 7.24−7.21 (m, 1H), 7.12−
7.06 (m, 1H), 5.58 (d, J = 8.4 Hz, 1H), 4.92−4.83 (m, 2H), 4.84−
4.80 (m, 2H), 4.40 (d, J = 5.6 Hz, 1H), 3.34−3.32 (m, 1H), 2.37−
2.18 (m, 1H), 2.24−2.00 (m, 3H), 1.80−0.93 (m, 20H), 0.88−0.77
(m, 3H), 0.66−0.56 (m, 3H). MS (ESI): mass calcd for C29H40BFO7,
530.3; m/z: found, 529.3 [M − H]−. HPLC: 100% in 220 nm; 100%
in 254 nm.
(3aR,4R,5R,7R,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methy l -7 - ( (R ) -ox i ran -2 -y l ) -3 -oxodecahydro -4 ,9a -
propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate (55). A
mixture of 6 (20.0 g, 37.5 mmol, 1.0 equiv) and m-chloroperox-
ybenzoic acid (8.9 g, 41.3 mmol, 1.1 equiv) in dichloromethane
(200.0 mL) was degassed and purged with N2 for three times, and
then the mixture was stirred at 25 °C for 12 h under an N2
atmosphere. The mixture was poured into ice−water (w/w = 1/1)
(100 mL). The combined organic phase was washed with aq
NaHCO3 (20 mL) and brine (100 mL), dried, ﬁltered, and
concentrated in vacuum. The residue was puriﬁed by silica gel
chromatography (petroleum ether/ethyl acetate = 1/1) to give
(3aR,4R,5R,7R,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-7-
((R)-oxiran-2-yl)-3-oxodecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-(tosyloxy)acetate (11.0 g, 20.0 mmol, 53.4% yield) as a
white solid.
A mixture of (3aR,4R,5R,7R,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-
t e t r ame thy l - 7 - ( (R ) -ox i r an -2 -y l ) - 3 -o xodecahyd ro -4 , 9 a -
propanocyclopenta[8]annulen-5-yl 2-(tosyloxy)acetate (2.0 g, 3.6
mmol, 1.0 equiv), 7-ﬂuoro-1-hydroxy-3H-2,1-benzoxaborol-6-ol
(612.9 mg, 3.6 mmol, 1.0 equiv), and Na2CO3 (1.2 g, 10.9 mmol,
3.0 equiv) in DMSO (30.0 mL) was degassed and purged with N2 for
three times, and then the mixture was stirred at 30 °C for 12 h under
an N2 atmosphere. The mixture was poured into ice−water (w/w =
1/1) (50 mL) and precipitating solid. The solid was collected to
aﬀord (3aR,4R,5R,7R,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-
7-((R)-oxiran-2-yl)-3-oxodecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((7-ﬂuoro-1-hydroxy-1,3-dihydrobenzo[c] [1,2]-
oxaborol-6-yl)oxy)acetate 55 (1.7 g) as a white solid. 1H NMR
(DMSO-d6, 400 MHz): δ 9.27 (s, 1H), 7.25−7.19 (m, 1H), 7.13 (d, J
= 8.4 Hz, 1H), 5.6 (d, J = 8.4 Hz, 1H), 4.97−4.90 (m, 2H), 4.89−
4.75 (m, 2H), 4.35 (d, J = 6.4 Hz, 1H), 3.48 (t, J = 6.4 Hz, 1H),
3.13−3.10 (m, 1H), 2.43−2.37 (m, 1H), 2.30−1.99 (m, 5H), 1.76−
1.57 (m, 3H), 1.55−1.23 (m, 6H), 1.18−0.97 (m, 3H), 0.93−0.75
(m, 6H), 0.64 (d, J = 7.2 Hz, 3H) MS (ESI): mass calcd for
C29H38BFO8, 544.26; m/z: found, 543.3 [M − H]−. HPLC: 96.6%
(220 nm), 100.0% (254 nm).
The following compounds are derived from (3aR,4R,5R,7R,8S,9-
R,9aS,12R)-7-formyl-8-hydroxy-4,7,9,12-tetramethyl-3-oxodecahydro-
4,9a-propanocyclopenta[8]annulen-5-yl 2-(tosyloxy)acetate 57, which
was prepared by reaction of (3aR,4R,5R,7R,8S,9R,9aS,12R)-7-formyl-
8 - h yd ro x y - 4 , 7 , 9 , 12 - t e t r ame thy l - 3 - o xodec ahyd ro - 4 , 9 a -
propanocyclopenta[8]annulen-5-yl 2-hydroxyacetate28 (56) and p-
toluenesulfonyl chloride in pyridine.
(3aR,4R,5R,7R,8S,9R,9aS,12R)-7-formyl-8-hydroxy-4,7,9,12-
tetramethyl-3-oxodecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((7-Fluoro-1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)oxy)acetate (58). A solution of 57 (300.0
mg, 561.1 μmol, 1.0 equiv), 80 (94.2 mg, 561.1 μmol, 1.0 equiv), and
Na2CO3 (178.41 mg, 1.68 mmol, 3.00 equiv) in DMSO (10.0 mL)
was heated to 30−40 °C for 12 h. Water (20 mL) was added to the
mixture, white solid was precipitated and ﬁltered to give a crude
product. The crude product was puriﬁed by prep HPLC to give
(3aR,4R,5R,7R,8S,9R,9aS,12R)-7-formyl-8-hydroxy-4,7,9,12-tetra-
methyl-3-oxodecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-
((7-ﬂuoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)-
acetate 58 (81.0 mg, 152.7 μmol, 27.2% yield, 10% purity) as a white
solid. 1H NMR (DMSO-d6, 400 MHz): δ 9.67 (s, 1H), 9.27 (s, 1H),
7.24 (t, J = 7.9 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 5.42 (d, J = 8.4 Hz,
1H), 4.92 (s, 2H), 4.86−4.75 (m, 3H), 3.57 (t, J = 6.6 Hz, 1H),
2.43−2.03 (m, 4H), 1.76−1.21 (m, 10H), 1.09 (s, 3H), 0.95 (d, J =
7.1 Hz, 3H), 0.89−0.80 (m, 2H), 0.62 (d, J = 7.1 Hz, 3H). MS (ESI):
mass calcd for C28H36BFO8, 530.3; m/z: found, 529.3 [M − H]−.
HPLC: 100% in 220 nm; 100% in 254 nm.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-7-(Hydroxymeth-
y l ) - 4 , 7 , 9 , 1 2 - t e t r ame thy l - 3 - o xode c ahyd ro - 4 , 9 a -
propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate (59). A sol-
ution of 57 (300.0 mg, 561.1 μmol, 1.0 equiv) and NaBH(OAc)3
(237.8 mg, 1.1 mmol, 2.0 equiv) in dichloromethane (15.0 mL) was
stirred at 20 °C for 2 h. Water (20 mL) was added to the mixture, the
aqueous layer was treated with dichloromethane (10 mL × 3), the
combined organic phase was treated with brine, dried and
concentrated in vacuo to give crude (3aR,4R,5R,7S,8S,9R,9aS,12R)-
8-hydroxy-7-(hydroxymethyl)-4,7,9,12-tetramethyl-3-oxodecahydro-
4,9a-propanocyclopenta[8]annulen-5-yl 2-(tosyloxy)acetate (300.0
mg, crude) as a colorless oil.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-7-(hydroxymethyl)-
4,7,9,12-tetramethyl-3-oxodecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-(tosyloxy)acetate (300.0 mg, 559.0 μmol, 1.0 equiv),
80 (93.9 mg, 559.0 μmol, 1.0 equiv), and Na2CO3 (177.7 mg, 1.7
mmol, 3.0 equiv) in DMSO (5.0 mL) were heated to 30−40 °C for
12 h. Water (20 mL) was added to the mixture; white solid was
precipitated and ﬁltered to give a crude product. The crude product
was puriﬁed by prep HPLC to give (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-
hydroxy-7-(hydroxymethyl)-4,7,9,12-tetramethyl-3-oxodecahydro-
4,9a-propanocyclopenta[8]annulen-5-yl 2-((7-ﬂuoro-1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate 59 (47.0 mg, 88.3
μmol, 15.8% yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz):
δ 9.26 (s, 1H), 7.22−7.20 (m, 1H), 7.10−7.00 (m, 1H), 5.55−5.53
(m, 1H), 5.17−5.15 (m, 1H), 4.92 (s, 1H), 4.83−4.72 (m, 3H),
4.56−4.48 (m, 2H), 3.90 (d, J = 11.0 Hz, 1H), 3.41 (d, J = 6.2 Hz,
1H), 3.32 (d, J = 11.0 Hz, 1H), 2.32−2.30 (m, 2H), 2.26−1.98 (m,
3H), 1.88−1.21 (m, 10H), 1.02 (s, 3H), 0.83 (d, J = 7.1 Hz, 3H),
0.61 (d, J = 6.6 Hz, 3H). MS (ESI): mass calcd for C28H38BFO8,
532.3; m/z: found, 531.3 [M − H]−. HPLC: 100% in 220 nm; 100%
in 254 nm.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-7-((hydroxyimino)-
methyl)-4,7,9,12-tetramethyl-3-oxodecahydro-4,9a-
propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate (60). A sol-
ution of 58 (400.0 mg, 754.2 μmol, 1.0 equiv) and hydroxylamine
hydrochloride (62.9 mg, 905.0 μmol, 1.2 equiv) in H2O (5.0 mL) and
ethanol (10.0 mL) were stirred at 15 °C for 12 h. HPLC and LCMS
showed the desired product as major component and starting material
consumed. Water (30 mL) was added to the mixture, white solid
precipitated, the mixture was ﬁltered to give a crude product. The
crude product was puriﬁed by prep HPLC. The solvent was
concentrated to about 15 mL and then lyophilized to give
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-7-((hydroxyimino)methyl)-
4,7,9,12-tetramethyl-3-oxodecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((7-ﬂuoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]-
oxaborol-6-yl)oxy)acetate 60 (99.0 mg, 174.3 μmol, 23.1% yield,
96.0% purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz): δ
10.41 (br s, 1H), 9.25 (br s, 1H), 7.51 (s, 1H), 7.23 (t, J = 7.9 Hz,
1H), 7.10 (d, J = 7.9 Hz, 1H), 5.55 (d, J = 7.9 Hz, 1H), 4.92 (s, 2H),
4.78 (s, 2H), 3.46 (d, J = 6.6 Hz, 1H), 2.41 (br s, 1H), 2.25−2.01 (m,
3H), 1.75−0.94 (m, 16H), 0.85 (d, J = 7.1 Hz, 3H), 0.62 (d, J = 6.6
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Hz, 3H). MS (ESI): mass calcd for C28H37BFNO8, 545.26; m/z:
found, 546.3 [M + H]+. HPLC: 96.2% in 220 nm; 100% in 254 nm.
( 3 a R , 4 R , 5 R , 7 S , 8 S , 9 R , 9 a S , 1 2 R ) - 8 - H y d r o x y - 7 -
((methoxyimino)methyl)-4,7,9,12-tetramethyl-3-oxodecahy-
dro-4,9a-propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-
hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate
(61). This compound was prepared in a manner similar to that
described for 60, using O-methyl hydroxylamine in place of
hydroxylamine. 1H NMR (DMSO-d6, 400 MHz): δ 9.25 (br s, 1H),
7.50 (s, 1H), 7.25 (t, J = 8.0 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 5.60
(d, J = 8.0 Hz, 1H), 4.92 (s, 2H), 4.78 (s, 2H), 3.62 (s, 3H), 3.48 (d, J
= 5.6 Hz, 1H), 2.41 (br s, 1H), 2.24−1.97 (m, 4H), 1.72−1.40 (m,
5H), 1.35−1.19 (m, 5H), 1.15−0.96 (m, 5H), 0.85 (d, J = 6.4 Hz,
3H), 0.63 (d, J = 5.6 Hz, 3H) MS (ESI): mass calcd for
C29H39BFNO8, 559.28; m/z: found, 560.3 [M + H]
+. HPLC: 97.5%
(220 nm), 100.0% (254 nm).
( 3 a R , 4 R , 5 R , 7 S , 8 S , 9 R , 9 a S , 1 2 R ) - 8 - H y d r o x y - 7 -
((isopropoxyimino)methyl)-4,7,9,12-tetramethyl-3-oxodeca-
hydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-
hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate
(62). This compound was prepared in a manner similar to that
described for 60, using O-isopropyl hydroxylamine in place of
hydroxylamine. 1H NMR (DMSO-d6, 400 MHz): δ 9.26 (br s, 1H),
7.47 (s, 1H), 7.23 (t, J = 8.0 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 5.57
(d, J = 8.0 Hz, 1H), 4.92 (s, 1H), 4.76 (s, 1H), 4.16 (dt, J = 5.6, 12.1
Hz, 1H), 3.48 (d, J = 5.2 Hz, 2H), 2.41 (br s, 1H), 2.09 (d, J = 15.6
Hz, 4H), 1.73−1.21 (m, 12H), 1.19−0.97 (m, 10H), 0.86 (d, J = 6.4
Hz, 3H), 0.63 (d, J = 6.4 Hz, 3H). MS (ESI): mass calcd for
C31H43BFNO8, 587.48; m/z: found, 586.3 [M − H]−. HPLC: 98.8%
(220 nm), 85.1% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-7-(Aminomethyl)-8-hydroxy-
4 , 7 , 9 , 1 2 - t e t r a m e t h y l - 3 - o x o d e c a h y d r o - 4 , 9 a -
propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate (63). To a
solution of 60 (570.0 mg, 1.0 mmol, 1.0 equiv) in methanol (10.0
mL) was added Raney−nickel (0.5 g) under an N2 atmosphere. The
suspension was degassed and purged with H2 for three times. The
mixture was stirred under H2 (50 psi) at 25 °C for 2 h. The reaction
mixture was ﬁltered and the ﬁlter was concentrated to give a residue,
which was puriﬁed by prep HPLC to give (3aR,4R,5R,7S,8S,9-
R,9aS,12R)-7-(aminomethyl)-8-hydroxy-4,7,9,12-tetramethyl -3-oxo-
decahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-((7-ﬂuoro-1-hy-
droxy-1,3-dihydro benzo[c][1,2]oxaborol-6-yl)oxy)acetate 63 (300.0
mg, 464.8 μmol, 44.2% yield, TFA) as a light yellow solid. 1H NMR
(DMSO-d6, 400 MHz): δ 9.27 (br s, 1H), 7.55 (br s, 2H), 7.25 (t, J =
7.6 Hz, 1H), 7.15−7.06 (m, 1H), 5.49−5.28 (m, 2H), 4.91 (br s, 1H),
4.78 (br s, 1H), 3.51 (br s, 1H), 3.18 (br s, 1H), 2.92 (br s, 1H), 2.42
(d, J = 8.4 Hz, 2H), 2.25−1.90 (m, 4H), 1.69−1.21 (m, 10H), 1.04
(br s, 3H), 0.84 (d, J = 5.6 Hz, 2H), 0.64 (d, J = 6.4 Hz, 3H) MS
(ESI): mass calcd for C30H40BF4NO9, 531.28; m/z: found, 532.3 [M
+ H]+. HPLC: 97.1% (220 nm), 93.6% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-7-((methylamino)methyl)-3-oxodecahydro-4,9a-
propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate (64). So-
dium cyanoborohydride (142.2 mg, 2.3 mmol, 4.0 equiv) was
added to a solution of 58 (300.0 mg, 565.6 μmol, 1.0 equiv) and
methylamine (4.0 equiv) in methanol (10.0 mL) and acetic acid (1.0
mL). The mixture was stirred at 15 °C for 12 h. Water (30 mL) was
added to the mixture, and the mixture was treated with dichloro-
methane (3 × 30 mL). The combined organic phase was concentrated
to give a crude product. The crude product was puriﬁed by prep
HPLC. The solvent was concentrated to about 15−20 mL of solution
left and then was lyophilized to give (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-
hydroxy-4,7,9,12-tetramethyl-7-((methylamino)methyl)-3-oxodecahy-
dro-4,9a-propanocyclopenta[8]annulen-5-yl 2-((7-ﬂuoro-1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate 64 (52.0 mg,
95.3 μmol, 16.8% yield) as a white TFA salt solid. 1H NMR
DMSO-d6, (400 MHz): δ 9.30 (br s, 1H), 8.01 (br s, 2H), 7.31 (t, J =
8.0 Hz, 1H), 7.13 (d, J = 7.8 Hz, 1H), 5.36 (d, J = 8.0 Hz, 1H), 4.93
(s, 2H), 4.87−4.71 (m, 2H), 3.47 (d, J = 5.3 Hz, 1H), 3.27 (d, J = 8.8
Hz, 1H), 3.12 (d, J = 10.5 Hz, 1H), 2.62−2.57 (m, 3H), 2.26−1.93
(m, 6H), 1.71−1.21 (m, 10H), 1.14−0.94 (m, 4H), 0.84 (d, J = 6.3
Hz, 3H), 0.64 (d, J = 7.0 Hz, 3H). MS (ESI): mass calcd for
C31H42BF4NO9, 545.3; m/z: found, 546.3 [M + H]
+. HPLC: 96.4% in
220 nm; 100% in 254 nm.
The following compounds were prepared in a manner similar to
that described for 64 from 58 and the appropriate amine.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-7-((Ethylamino)methyl)-8-hy-
droxy-4 ,7 ,9 ,12- tetramethyl -3 -oxodecahydro-4 ,9a-
propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate (65). 1H
NMR (DMSO-d6, 400 MHz): δ 9.28 (br s, 1H), 7.88 (br s, 1H),
7.73 (br s, 1H), 7.31 (t, J = 8.2 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H),
5.42 (br s, 1H), 5.36 (d, J = 8.4 Hz, 1H), 4.93 (s, 2H), 4.86−4.74 (m,
2H), 3.49 (d, J = 5.7 Hz, 1H), 3.33−3.22 (m, 1H), 3.14−2.94 (m,
3H), 2.42 (br s, 1H), 2.25−1.94 (m, 4H), 1.72−0.94 (m, 18H), 0.84
(d, J = 7.1 Hz, 2H), 0.64 (d, J = 7.1 Hz, 3H). MS (ESI): mass calcd
for C32H44BF4NO9, 559.3; m/z: found, 560.3 [M + H]
+. HPLC:
98.2% in 220 nm; 100% in 254 nm.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-((propylamino)methyl)decahydro-4,9a-
propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate (66). 1H
NMR (DMSO-d6, 400 MHz): δ 9.29 (br s, 1H), 7.96 (br s, 2H),
7.77 (br s, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.11 (d, J = 7.9 Hz, 1H),
5.48 (br s, 1H), 5.35 (d, J = 7.9 Hz, 1H), 4.93 (s, 2H), 4.87−4.75 (m,
2H), 3.49 (d, J = 5.7 Hz, 1H), 3.29 (t, J = 10.1 Hz, 1H), 3.17−3.04
(m, 1H), 2.97−2.82 (m, 2H), 2.41 (br s, 1H), 2.24−1.91 (m, 4H),
1.75−0.95 (m, 17H), 0.90−0.79 (m, 4H), 0.65 (d, J = 7.1 Hz, 3H).
MS (ESI): mass calcd for C33H46BF4NO9, 573.3; m/z: found, 574.3
[M + H]+. HPLC: 98.9% in 220 nm; 100% in 254 nm.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-7-((Butylamino)methyl)-8-hy-
droxy-4 ,7 ,9 ,12- tetramethyl -3 -oxodecahydro-4 ,9a-
propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate (67). 1H
NMR (DMSO-d6, 400 MHz): δ 9.28 (br s, 1H), 7.97 (br s, 1H),
7.76 (br s, 1H), 7.31 (t, J = 8.2 Hz, 1H), 7.11 (d, J = 7.9 Hz, 1H),
5.35 (d, J = 8.4 Hz, 1H), 4.92 (s, 2H), 4.86−4.75 (m, 2H), 3.49 (d, J
= 6.2 Hz, 1H), 3.28 (t, J = 9.9 Hz, 1H), 3.18−3.06 (m, 1H), 2.93 (br
s, 2H), 2.42 (br s, 1H), 2.25−1.91 (m, 5H), 1.73−1.20 (m, 15H),
1.17−0.96 (m, 4H), 0.90−0.79 (m, 5H), 0.65 (d, J = 6.6 Hz, 3H). MS
(ESI): mass calcd for C34H48BF4NO9, 587.3; m/z: found, 588.5 [M +
H]+. HPLC: 98.6% in 220 nm; 91.6% in 254 nm.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-7-((Cyclopropylamino)-
methyl)-8-hydroxy-4,7,9,12-tetramethyl-3-oxodecahydro-
4,9a-propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-hy-
droxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate
(68). 1H NMR (DMSO-d6, 400 MHz): δ 9.29 (br s, 1H), 8.29 (br s,
1H), 7.99 (br s, 1H), 7.32 (t, J = 8.2 Hz, 1H), 7.12 (d, J = 7.9 Hz,
1H), 5.42 (d, J = 8.4 Hz, 2H), 4.93 (s, 2H), 4.87−4.75 (m, 2H), 3.48
(d, J = 6.2 Hz, 1H), 3.39−3.22 (m, 2H), 2.73 (br s, 1H), 2.42 (br s,
1H), 2.25−1.91 (m, 5H), 1.74−1.22 (m, 10H), 1.13−0.92 (m, 6H),
0.89−0.68 (m, 6H), 0.65 (d, J = 7.1 Hz, 3H). MS (ESI): mass calcd
for C33H44BF4NO9, 571.3; m/z: found, 572.3 [M + H]
+. HPLC:
97.7% in 220 nm; 100% in 254 nm.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-7-((Dimethylamino)methyl)-8-
hydroxy-4,7,9,12-tetramethyl-3-oxodecahydro-4,9a-
propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate (69). 1H
NMR (DMSO-d6, 400 MHz): δ 9.29 (br s, 1H), 8.81 (br s, 1H),
7.27 (t, J = 7.7 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 5.94 (br s, 1H),
5.35 (d, J = 7.9 Hz, 1H), 4.93 (s, 2H), 4.83 (br s, 2H), 3.72−3.40 (m,
4H), 3.10 (d, J = 13.2 Hz, 1H), 2.86−2.84 (m, 4H), 2.41 (br s, 1H),
2.27−1.99 (m, 4H), 1.77−1.18 (m, 12H), 1.12−0.96 (m, 2H), 0.88
(d, J = 6.2 Hz, 3H), 0.65 (d, J = 5.7 Hz, 3H). MS (ESI): mass calcd
for C32H44BF4NO9, 559.3; m/z: found, 560.3 [M + H]
+. HPLC:
96.8% in 220 nm; 100% in 254 nm.
(3aR,4R,5R,7S,8S,9R,9aS,12R)-7-(Acetamidomethyl)-8-hy-
droxy-4 ,7 ,9 ,12- tetramethyl -3 -oxodecahydro-4 ,9a-
propanocyclopenta[8]annulen-5-yl 2-((7-Fluoro-1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate (70). A
mixture of 63 (300.0 mg, 564.5 μmol, 1.0 equiv), acetic anhydride
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(63.4 mg, 620.9 μmol, 1.1 equiv), acetic acid (67.8 mg, 1.1 mmol, 2.0
equiv) in dichloromethane (20.0 mL) was degassed and purged with
N2 for three times, and then the mixture was stirred at 60 °C for 12 h
under an N2 atmosphere. LC/MS showed 63 was consumed
completely and one main peak with desired MS was detected. The
solvent was removed. The residue was puriﬁed by prep HPLC to give
(3aR,4R,5R,7S, 8S,9R,9aS,12R)-7-(acetamidomethyl)-8-hydroxy-
4,7,9,12-tetramethyl-3-oxodecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl 2-((7-ﬂuoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]-
oxaborol-6-yl)oxy)acetate 70 (97.0 mg, 169.1 μmol, 29.9% yield) as
a white solid. 1H NMR (DMSO-d6, 400MHz): δ 7.28 (t, J = 8.4 Hz,
1H), 7.09 (d, J = 8.4 Hz, 1H), 7.00−6.94 (m, 1H), 5.51 (d, J = 8.4
Hz, 1H), 4.90 (s, 2H), 4.85−4.74 (m, 2H), 3.60 (dd, J = 6.4, 13.8 Hz,
1H), 3.43 (d, J = 5.6 Hz, 1H), 3.00 (dd, J = 4.4, 13.8 Hz, 1H), 2.36
(br s, 1H), 2.31 (br s, 1H), 2.23−1.99 (m, 3H), 1.94−1.82 (m, 1H),
1.81−1.73 (m, 2H), 1.69−1.55 (m, 2H), 1.48 (br s, 1H), 1.40−1.20
(m, 6H), 1.05−0.87 (m, 4H), 0.83 (d, J = 6.4 Hz, 2H), 0.62 (d, J =
6.4 Hz, 3H) MS (ESI): mass calcd for C30H41BFNO8, 573.29; m/z:
found, 574.3 [M + H]+. HPLC: 100.0% (220 nm), 100.0% (254 nm).
2-Tetramethyl-3-oxodecahydro-4,9a-propanocyclopenta-
[8]annulen-5-yl 2-((7-Fluoro-1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)oxy)acetate (71). To a solution of 70 (1.0 g,
1.8 mmol, 1.0 equiv) in ethanol (15.0 mL) was added pyridin-1-ium-
1-ylboranuide (1.7 g, 17.9 mmol, 10.0 equiv). Subsequently,
methanol/HCl (4 M, 8.0 mL, 17.9 equiv) was added under an N2
atmosphere at 0 °C. The mixture was stirred at 25 °C for 12 h. The
mixture was adjusted to pH ≈ 6 with saturated NaHCO3 and
extracted with ethyl acetate (20 mL × 2). After concentrated in vacuo,
the residue was puriﬁed by prep HPLC to aﬀord (3aR,4R,5R,7S,8S,9-
R,9aS,12R)-8-hydroxy-7-((methoxyamino)methyl)-4,7,9,12-tetra-
methyl-3-oxodecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-
((7-ﬂuoro-1-hydroxy-1,3-dihydro-benzo[c][1,2]oxaborol-6-yl)oxy)-
acetate 71 (432.0 mg, 769.4 μmol, 43.0% yield) as a white solid. 1H
NMR (DMSO-d6, 400 MHz): δ 7.28 (t, J = 8.0 Hz, 1H), 7.12 (d, J =
8.0 Hz, 1H), 5.45−5.36 (m, 1H), 4.93 (s, 2H), 4.81 (d, J = 2.4 Hz,
2H), 4.31 (d, J = 5.6 Hz, 1H), 3.77−3.71 (m, 4H), 3.50−3.44 (m,
1H), 3.26 (t, J = 13.2 Hz, 1H), 2.40 (br s, 1H), 2.23−1.93 (m, 4H),
1.77−1.23 (m, 10H), 1.19−0.97 (m, 4H), 0.87 (d, J = 6.4 Hz, 3H),
0.65 (dd, J = 3.2, 6.8 Hz, 3H). MS (ESI): mass calcd for
C31H42BF4NO10, 561.29; m/z: found, 562.4 [M + H]
+. HPLC:
95.4% (220 nm), 95.1% (254 nm).
(3aR,4R,5R,7S,9R,9aS,12R)-4,7,9,12-Tetramethyl-3,8-dioxo-
7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl (1-
Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)carbamate
(74). Trichloromethylchloroformate (215.0 mL, 1.5 mmol) and
triethylamine (495.0 mL, 3.6 mmol) were added to an ice cooled
solution of (3R,3aR,4R,5R,7S,9R,9aR,12R)-5-hydroxy-3-methoxy-
4,7,9,12-tetramethyl-7-vinyloctahydro-4,9a-propanocyclopenta[8]-
annulen-8(9H)-one 72 (1.0 g, 3.0 mmol) in THF (10 mL). The
mixture was stirred at room temperature for 2 h and then treated with
further quantities of trichloromethylchloroformate (215.0 mL, 1.5
mmol) and triethylamine (495.0 mL, 3.6 mmol). After a further 2 h,
the mixture was diluted with ethyl acetate and washed with brine. The
organic phase was dried and concentrated to give (3R,3aR,4R,5R,7S,9-
R,9aR,12R)-3-methoxy-4,7,9,12-tetramethyl-8-oxo-7-vinyldecahydro-
4,9a-propanocyclopenta[8]annulen-5-yl carbonochloridate 73 without
further puriﬁcation (1.2 g, 100.0%).
To a solution of 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol (200.0
mg, 1.4 mmol) in dichloromethane (15 mL) was added triethylamine
(137.0 mg, 1.4 mmol) and 73 (1.2 g, 3.0 mmol). The reaction mixture
was stirred at room temperature overnight, at which time TLC
showed the starting materials were consumed completely. The
mixture was extracted with ethyl acetate, washed with brine, dried,
and concentrated in vacuo give the crude intermediate, to which was
added a solution of zinc chloride in concentrated HCl. The mixture
was stirred at room temperature for 0.5 h. Then, the mixture was
added water and extracted with ethyl acetate. The crude product was
puriﬁed by prep HPLC to give (3aR,4R,5R,7S,8S,9R, 9aS,12R)-8-
hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-
propanocyclopenta[8]annulen-5-yl (1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-6-yl)carbamate 74 (61.0 mg). 1H NMR (DMSO-d6,
400 MHz): δ 9.38 (s, 1H), 7.89 (s, 1H), 7.43 (d, J = 7.6 Hz, 1H),
7.27 (d, J = 8.0 Hz, 1H), 6.26 (m, 1H), 5.58 (s, 1H), 5.13 (m, 2H),
4.89 (s, 2H), 2.38 (m, 1H), 2.05 (m, 4H), 1.06−1.50 (m, 13H), 1.07
(m, 4H), 0.82 (d, 3H), 0.69 (d, 3H).
The following compounds were prepared from 73 in a similar
manner:
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl (5-Fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]-
oxaborol-6-yl)carbamate (75). 1H NMR (DMSO-d6, 400 MHz):
δ 9.25 (s, 2H), 7.99 (s, 1H), 7.32 (d, J = 10.4 Hz, 1H), 6.74 (dd, J =
10.8, 17.6 Hz, 1H), 5.64 (d, J = 9.6 Hz, 1H), 5.29 (d, J = 10.8 Hz,
1H), 4.98 (m, 3H), 3.40 (s, 1H), 3.12 (s, 3H), 2.88 (m, 1H), 2.34 (m,
1H), 2.04 (s, 3H), 1.90 (m, 1H), 1.72 (m, 1H), 1.67 (d, 2H), 1.43
(m, 2H), 1.25−1.07 (m, 9H), 0.87−0.75 (m, 5H). MS (ESI): mass
calcd for C29H39BNO6, 527.2; m/z: found, 526.2 [M − H]−. HPLC:
99.6% (220 nm), 100% (254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl ((1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-
6-yl)methyl)carbamate (76). 1H NMR (DMSO-d6, 400 MHz): δ
7.70 (t, J = 5.8 Hz, 1H), 7.61 (s, 1H), 7.38−7.33 (m, 2H), 6.74 (dd, J
= 10.8, 17.6 Hz, 1H), 5.53 (d, J = 9.6 Hz, 1H), 5.24 (d, J = 10.4 Hz,
1H), 4.96−4.90 (m, 3H), 4.32−4.16 (m, 2H), 3.13−3.10 (m, 3H),
2.85 (d, J = 6.4 Hz, 1H), 2.36−2.33 (m, 1H), 2.07−1.61 (m, 5H),
1.41−1.38 (m, 2H), 1.18−1.01 (m, 11H), 0.90 (d, J = 6.4 Hz, 3H),
0.78 (d, J = 6.8 Hz, 3H). MS (ESI): mass calcd for C30H42BNO6,
523.3; m/z: found, 522.2 [M − H]−. HPLC: 99.0% (220 nm), 100%
(254 nm).
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetra-
methyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]-
annulen-5-yl ((7-Fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]-
oxaborol-6-yl)methyl)carbamate (77). 1H NMR (DMSO-d6,
400 MHz): δ 9.23 (s, 1H), 7.50 (t, J = 6.0 Hz, 1H), 7.38 (t, J =
7.2 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.20 (dd, J = 11.2, 18.0 Hz,
1H), 5.41 (d, J = 8.8 Hz, 1H), 5.09−4.86 (m, 4H), 4.25−4.10 (m,
2H), 3.38 (d, J = 5.6 Hz, 1H), 2.29 (s, 1H), 2.22−1.95 (m, 4H),
1.69−1.14 (m, 10H), 1.06−0.88 (m, 4H), 0.78 (d, J = 6.6 Hz, 3H),
0.62 (d, J = 5.2 Hz, 3H). MS (ESI): mass calcd for C29H39BFNO6,
527.29; m/z: found, 526.3 [M − H]−. HPLC: 100% (220 nm), 100%
(254 nm).
( 3 a R , 4 R , 5 R , 7 S , 8 S , 9 R , 9 a S , 1 2 R ) - 8 - H y d r o x y - 7 -
( (me thox yam ino )me thy l ) - 4 , 7 , 9 , 1 1 , 2 - d iﬂuo ro - 3 -
(methoxymethoxy)benzene 80. To a solution of 2,3-diﬂuorophe-
nol (300.0 g, 2.3 mol, 1.0 equiv) in dichloromethane (1.5 L) was
added methoxymethyl chloride (278.9 g, 3.5 mol, 1.5 equiv) and
DIEA (597.1 g, 4.6 mol, 2.0 equiv). The mixture was stirred at 0 °C
for 2 h. TLC indicated that starting material was consumed. The
reaction mixture was quenched by addition of H2O (1500 mL) at 0
°C and then was adjusted to pH = 6. The combined organic layers
were washed with saturation NH4Cl (3 × 500 mL), dried, ﬁltered, and
concentrated under reduced pressure to give a residue. 1,2-Diﬂuoro-3-
(methoxymethoxy)benzene (400.0 g, 2.3 mol, 99.4% yield) was
obtained as yellow oil, which was used into the next step without
further puriﬁcation. 1H NMR (CDCl3, 400 MHz): δ 7.03−6.93 (m,
1H), 6.89−6.78 (m, 1H), 5.28−5.20 (m, 2H), 3.58−3.50 (m, 3H).
3,4-Diﬂuoro-2-(methoxymethoxy)benzaldehyde 81. To a
solution of 80 (100.0 g, 574.3 mmol, 1.0 equiv) in THF (1.5 L)
was added n-butyllithium (2.5 M, 298.6 mL, 1.3 equiv). The mixture
was stirred at −78 °C for 7 h. Then, ethyl formate (85.1 g, 1150
mmol, 2.0 equiv) was added and the mixture was stirred for another 1
h. TLC indicated that starting material was consumed completely.
The reaction mixture was quenched by addition of H2O (1000 mL) at
0 °C and then was extracted with ethyl acetate (3 × 800 mL). The
combined organic layers were washed with brine 1000 mL, dried,
ﬁltered, and concentrated under reduced pressure to give a residue.
The 3,4-diﬂuoro-2-(methoxymethoxy)benzaldehyde 81 (492.0 g,
crude) as a yellow oil was used into the next step without further
puriﬁcation. 1H NMR (CDCl3, 400 MHz): δ 10.40−10.29 (m, 1H),
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7.73−7.57 (m, 1H), 7.11−6.98 (m, 1H), 5.33 (s, 2H), 3.63−3.58 (m,
3H).
4-(Benzyloxy)-3-ﬂuoro-2-(methoxymethoxy)benzaldehyde
82. To a solution of 81 (256.0 g, 1.27 mol, 1.0 equiv) in DMF (1.5 L)
was added Cs2CO3 (618.9 g, 1.90 mol, 1.5 equiv) and benzyl alcohol
(136.9 g, 1.3 mol, 1.0 equiv). The mixture was stirred at 70 °C for 10
h. TLC indicated that starting material was consumed completely.
The reaction mixture was quenched by addition of H2O (1000 mL) at
0 °C, then diluted with ethyl acetate (1200 mL), and extracted with
ethyl acetate (1200 mL × 2). The combined organic layers were
washed with H2O (2 × 1000 mL), dried, ﬁltered, and concentrated
under reduced pressure to give a residue. 4-(Benzyloxy)-3-ﬂuoro-2-
(methoxymethoxy)benzaldehyde 82 (400.0 g, crude) was obtained as
a yellow oil, which was used into the next step without further
puriﬁcation.
4-(Benzyloxy)-3-ﬂuoro-2-hydroxybenzaldehyde 83. To a
solution of 82 (760.0 g, 2.6 mol, 1.0 equiv) in CH3OH (600.0 mL)
was added aq HCl (2 M, 200.0 mL). The mixture was stirred at 40 °C
for 4 h. TLC indicated that starting material was consumed
completely. The reaction was quenched by addition of H2O (300
mL) and the mixture was concentrated under reduced pressure to
remove methanol. The residue was diluted with dichloromethane 500
mL and extracted with dichloromethane 1000 mL (2 × 500 mL). The
combined organic layers were washed with brine (3 × 500 mL), dried,
ﬁltered, and concentrated under reduced pressure to give a residue.
The residue was puriﬁed by column chromatography (SiO2,
petroleum ether/ethyl acetate = 20:1 to 5:1). 4-(Benzyloxy)-3-
ﬂuoro-2-hydroxybenzaldehyde 83 (225.0 g, 913.8 mmol, 34.9% yield)
was obtained as a black-brown solid. 1H NMR (DMSO-d6, 400
MHz): δ 10.97 (s, 1H), 10.06 (s, 1H), 7.34−7.52 (m, 6H), 6.90−6.98
(m, 1H), 5.28 (s, 2H).
3-(Benzyloxy)-2-ﬂuoro-6-formylphenyl Triﬂuoromethane-
sulfonate 84. To a solution of 83 (117.0 g, 475.2 mmol, 1.0
equiv), pyridine (75.2 g, 950.3 mmol, 2.0 equiv) and 4-
dimethylaminopyridine (5.8 g, 47.5 mmol, 0.1 equiv) in dichloro-
methane (1.5 L) was added Tf2O (201.1 g, 712.8 mmol, 1.5 equiv)
dropwise. The mixture was stirred at 0 °C for 2 h. HPLC indicated
that starting material was consumed completely. The reaction mixture
was quenched by addition of H2O (1000 mL) and then extracted with
dichloromethane (2 × 1000 mL). The combined organic layers were
washed with brine (500 mL), dried, ﬁltered, and concentrated under
reduced pressure to give a residue. The residue was puriﬁed by
column chromatography (SiO2, petroleum ether/ethyl acetate = 20:1
to 2:1). 3-(Benzyloxy)-2-ﬂuoro-6-formylphenyl triﬂuoromethanesul-
fonate 84 (150.0 g, 396.5 mmol, 83.5% yield) was obtained as a
yellow oil. 1H NMR (CDCl3, 400 MHz): δ 10.08 (s, 1H), 7.71 (d, J =
7.8 Hz, 1H), 7.49−7.36 (m, 5H), 7.19−7.13 (m, 1H), 5.28 (s, 2H).
4-(Benzyloxy)-3-ﬂuoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)benzaldehyde 85. To a solution of 84 (52.0 g, 137.5
mmol, 1.00 equiv), potassium acetate (40.5 g, 412.4 mmol, 3.0 equiv),
and dipinacol diborane (104.7 g, 412.4 mmol, 3.0 equiv) in dioxane
(1.0 L) was added Pd(dppf)Cl2 (2.0 g, 2.75 mmol, 0.02 equiv). The
mixture was stirred at 70 °C for 16 h. HPLC indicated that starting
material was consumed completely. The reaction mixture was ﬁltered
and concentrated under reduced pressure to give a residue. The
residue was puriﬁed by column chromatography (SiO2, petroleum
ether/ethyl acetate = 50:1 to 5:1). 4-(Benzyloxy)-3-ﬂuoro-2-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde 85 (37.0 g, 103.9
mmol, 75.6% yield) was obtained as a white solid. 1H NMR (DMSO-
d6, 400 MHz): δ 9.81 (d, J = 3.0 Hz, 1H), 7.81 (d, J = 8.3 Hz, 1H),
7.54−7.33 (m, 7H), 5.31 (s, 2H), 1.39−1.28 (m, 12H).
6-(Benzyloxy)-7-ﬂuorobenzo[c][1,2]oxaborol-1(3H)-ol 86.
To a solution of 85 (20.0 g, 56.2 mmol, 1.00 equiv) in THF (50.0
mL) was added NaBH4 (3.2 g, 84.2 mmol, 1.5 equiv). The mixture
was stirred at 0 °C for 1 h. TLC indicated that starting material was
consumed completely. The reaction mixture was quenched by
addition H2O (100 mL) at 0 °C, then adjusted pH = 5, removed
the THF, then ﬁltered, and concentrated under reduced pressure to
give a residue. 6-(Benzyloxy)-7-ﬂuorobenzo[c][1,2]oxaborol-1(3H)-
ol 86 (43.0 g, 166.6 mmol, 98.9% yield) was obtained as a white solid.
1H NMR (DMSO-d6, 400 MHz): δ 7.31−7.48 (m, 5H), 7.17 (t, J =
7.78 Hz, 1H), 7.01 (d, J = 8.03 Hz, 1H), 5.18 (s, 2H), 5.04 (s, 2H),
4.89 (s, 1H).
7-Fluorobenzo[c][1,2]oxaborole-1,6(3H)-diol 87. To a sol-
ution of 86 (15.0 g, 58.1 mmol, 1.0 equiv) in ethyl acetate (400.0 mL)
was added Pd/C (2.0 g). The mixture was stirred at 25 °C for 2 h
under an H2 atmosphere (50 psi). TLC indicated that starting
material was consumed completely. The reaction mixture was ﬁltered
and concentrated under reduced pressure to give a residue. 7-
Fluorobenzo[c][1,2]oxaborole-1,6(3H)-diol 87 (7.0 g, 41.7 mmol,
71.7% yield) was obtained as a white solid. 1H NMR (DMSO-d6, 400
MHz): δ 9.59 (s, 1H), 9.14 (s, 1H), 7.05−7.12 (m, 1H), 6.97−7.03
(m, 1H), 4.88 (s, 2H). MS (ESI): mass calcd for C7H6BFO3, 168.04;
m/z: found, 167.1 [M − H]−. HPLC: 92.5% (220 nm), 94.4% (254
nm).
Anti-wAlb High-Content in Vitro Assay. C6/36 cells (ECACC
#89051705, derived from Aedes albopictus larvae) were infected with
Wolbachia pipientis derived from the supernatant of cultured A.
albopictus Aa23 cells to create a stably Wolbachia-infected cell line
C6/36 (wAlbB). This cell line was subpassaged 6−8 days prior to
plating out at a density of 2000 viable cells per well in a 384-well
CellCarrier plate suspended in Liebovitz media supplemented with
20% fetal bovine serum, 2% tryptose phosphate broth, and 1% non-
essential amino acids. Compounds were dissolved and diluted in
DMSO, and compound solution was added to each well to provide a
ﬁnal DMSO concentration <1% and a total volume of 100 μL per
well.
Following 7 days of sterile incubation at 26 °C, staining media-
containing SYTO 11 DNA dye was added to each well. After 15 min,
all media was removed from each well and fresh media (no stain) was
added. Imaging of each well was accomplished using a PerkinElmer
Operetta high-content imaging system. Five ﬁelds per well were
imaged using a confocal 60× objective with the ﬂuorescein ﬁlter
(excitation ﬁlter: 460−490 nm; emission ﬁlter: 500−550 nm). Images
were analyzed using the PerkinElmer Harmony software to score each
intact cell on the basis of texture complexity of the cytoplasm. Full
details of the image analysis have been published.25
Compound sample wells were analyzed and normalized (along with
the positive controls) against the vehicle (untreated) control to give a
percentage reduction of Wolbachia-infected cells. Using the cell
number analysis, compounds with a host cell number amounting to
less than 50% of the vehicle control were classiﬁed as toxic and
retested at a reduced compound concentration. Dose−response
curves were generated with percentage reduction of Wolbachia-
infected cells versus compound concentration, using 5−10 compound
serial dilutions. Data were analyzed and compound EC50’s determined
using a 4-parameter logistic nonlinear regression model. EC50 is
deﬁned as the compound concentration producing a 50% reduction of
Wolbachia in the C6/36 cell line.
Anti-wMel Wolbachia High-Content in Vitro Assay. The
assay was developed based on previous work25 and carried out as
previously described.50 Brieﬂy, D. melanogaster LDW1 cells naturally
infected with wMel strain of Wolbachia were maintained in Shields
and Sang M3 (SSM3) Insect Medium (Sigma, S3652) supplemented
with 10% heat-inactivated fetal bovine serum (FBS) (qualiﬁed, One
Shot Format, Gibco, 26140-111) at 25 °C, in ﬂasks with unvented
caps. Greiner 1536-well assay plates (Part. no. 789091) were coated
with 1 mg/mL solution of Concanavalin-A lectin (MP Biomedicals,
02195283) to facilitate cell adhesion. Compounds were acoustically
transferred into plates using the Echo 555 Liquid Handler (Labcyte
Inc.). Cells were seeded at 4000 cells/well in SSM3 medium
supplemented with 2% FBS using the MultiFlo FX Multi-Mode
Dispenser (Biotek). After incubating at 25 °C for 6 days, the cells
were ﬁxed with 4% paraformaldehyde (PFA) for at least 10 min and
washed with phosphate buﬀered saline, pH 7, 0.1% Tween 20.
Fluorescence in situ hybridization (FISH) was used to stain
Wolbachia and 3 μM DAPI was used to stain DNA. The “bottle
valve” dispenser with an angled-head (Kalypsys Inc, San Diego, CA)
was used for ﬁxation and staining. Stained cells were imaged using the
CX5 Insight Cellomics high-content imaging instrument with a 10×
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objective (Thermo). Each well was analyzed using Compartmental
Analysis in HCS Studio (Thermo) for cell number and Wolbachia
content. Analysis outputs included (1) the total object number per
well and (2) the total ﬂuorescence intensity of all spots within each
cell (averaged per well). Data were analyzed in Genedata Screener,
Version 13.0.1-Standard by normalizing to DMSO (neutral) and
inhibitor control-treated wells (12.5 μM doxycycline and 125 nM
rifampicin). To determine the EC50’s, dose response curves (11′
point, 1:3 dilution) were ﬁtted using the four parameter Hill equation.
Each compound was tested in triplicate.
Ethics Statement on Animal Studies. All in vivo experiments
involving B. malayi were conducted at the Liverpool School of
Tropical Medicine (LSTM), were approved by the ethical committees
of the University of Liverpool and LSTM, and were conducted
according to Home Oﬃce (UK) requirements. All animal experi-
ments with L. sigmodontis were conducted at the Institute for Medical
Microbiology, Immunology and Parasitology (IMMIP), University
Hospital of Bonn, in accordance to the European Union animal
welfare guidelines. All protocols were approved by the local
authorities (Landesamt für Natur, Umwelt und Verbraucherschutz,
Cologne, Germany (AZ 84-02.04.2015.A507; 84-02.04.2012.A140).
In vivo pharmacokinetic studies in mice were conducted either at
Anacor Pharmaceuticals or Shanghai ChemPartner under appropriate
review by Institutional Animal Care and Use Committees (IACUC)
at each site.
B. malayi SCID Mouse Infection Models. A B. malayi SCID
mouse infection model for anti-Wolbachia drug screening was used as
previously described34,51−53 In brief, B. malayi L3 larvae were
generated by membrane blood feeding Liverpool strain ﬁlarial
susceptible Aedes aegypti mosquitoes with microﬁlariae isolated from
patently infectedMeriones unguiculatus gerbils. CB.17 SCID mice were
purchased from Charles River UK. Groups of 3 or 5 SCID mice were
infected with either 50 or 100 L3, ip, for larval or adult B. malayi
eﬃcacy testing, respectively. Drugs were dosed from point of infection
for larval testing or after an incubation period of 6 weeks for adult-
stage testing with variable length washout. Test drugs were
administered orally at indicated doses and as detailed below.
Doxycycline or minocycline positive controls were administered in
water at indicated doses. At 2-weeks (larval testing) or 12-weeks post-
infection (adult testing) motile B. malayi L4 or female parasites were
isolated by peritoneal lavage, enumerated by microscopy and
individually snap frozen. Total genomic DNA was isolated per
worm, and QPCR quantiﬁcations of single copy B. malayi Wolbachia
were undertaken per group of 10 worms per treatment/control, as
previously described.34,54 Eﬃcacy of Wolbachia depletion is reported
as median Wolbachia load per drug group expressed as a percentage of
median vehicle control levels from animals treated only with vehicle.
L. sigmodontis in Vivo Mouse Model. Female BALB/c wild
type mice were obtained from Janvier (Saint-Berthevin, France) and
were housed at the animal facility of the IMMIP in individually
ventilated cages on a 12 h light/dark cycle with food and water ad
libidum. Mice were infected at 6−8 weeks of age via exposure to the
natural mite vector Ornithonyssus bacoti containing infectious L.
sigmodontis L3 larvae.36 To compare the infection, the same batch of
mite-containing bedding was used to infect all animals of one
experiment. Then, 35 days post infection, time point adult worms
have developed within the thoracic cavity, and mice were treated per
oral gavage with the test compounds at concentrations indicated in
the result section. As a vehicle, 1% CMC + 0.1% Tween80 was used.
Negative controls were treated with vehicle only, and as a positive
control, mice were treated orally with doxycycline (Sigma) in 10%
DMSO/1× PBS. Necropsies were performed at 64−77 days post-
infection using an overdose of isoﬂurane (Baxter, Germany) and adult
worms were isolated from the thoracic cavity and peritoneum and
enumerated. Realtime PCR was performed from remaining female
adult worms to quantify Wolbachia FtsZ and L. sigmodontis actin
values by qRT-PCR as previously described.35
General PK Study Protocol. Animals were allowed to acclimate a
minimum of 72 h prior to selection for study. On the morning of
dosing, animals were weighed and grouped randomly. Animals
received the test material by tail-vein injection (IV), or oral gavage
(PO). After dosing, all clinical signs and observations were recorded,
and if adverse eﬀects were noted, the exact time that the animals
returned to normal was also recorded. At prescribed timepoints,
animals were anesthetized by isoﬂurane inhalation and blood samples
were collected via retro-orbital bleed or cardiac puncture. After the
blood sample collection, animals were euthanized by CO2 inhalation
followed by cervical dislocation.
Blood samples were collected into microtainer tubes (K2EDTA) on
ice and processed to provide plasma by centrifugation for 6 min at
approximately 2000g or 6000 rpm. Processed samples were
transferred to analysis tubes that were placed on dry ice. Samples
were analyzed by LC/MS/MS.
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Schulz, U.; Koschel, M.; Sternberg, S.; Martin, C.; Ford, L.; Taylor,
M. J.; Hoerauf, A. Combinations of registered drugs reduce treatment
times required to deplete Wolbachia in the Litomosoides sigmodontis
mouse model. PLoS Neglected Trop. Dis. 2018, 12, e0006116.
(36) Volkmann, L.; Fischer, K.; Taylor, M.; Hoerauf, A. Antibiotic
therapy in murine filariasis (Litomosoides sigmodontis): comparative
effects of doxycycline and rifampicin on Wolbachia and filarial
viability. Trop. Med. Int. Health 2003, 8, 392−401.
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